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CHAPTER 1 
MAGNETIC NANOMATERIALS FOR PRENATAL DIAGNOSIS  
 
1.1 Introduction 
1.1.1 Prenatal Diagnosis:  
Prenatal Diagnosis is an important procedure that provides pivotal information on the genetic 
health and other abnormalities of fetus.  The prenatal diagnostic procedures help clinicians and 
parents to strategize health management and treatment options after birth (Bolnick et al, 2014). 
Prenatal diagnosis helps the parents by giving them adequate time to mentally and emotionally 
cope with the health condition of the baby and also allows them to plan and manage the 
remaining weeks of pregnancy. Currently, prenatal diagnosis is mostly limited to high risk 
pregnancies. High risk pregnancies entail potential risk factors like maternal age (greater than 35 
or under 17), medical conditions that exist before pregnancy (High blood pressure, Diabetes, 
Genetic diseases) or medical conditions that develop during pregnancy (Preeclampsia, 
Gestational Diabetes) (Shajpal et al, 2017).  Amniocentesis and Chorionic Villus Sampling 
(CVS) are two invasive prenatal diagnostic procedures currently used in clinics.  Amniocentesis 
is usually performed in second trimester and involves collection of amniotic fluid from the 
mother’s sac via a syringe, while CVS is performed at end of first trimester to end of second 
trimester (week 12- 17) and involves removal of tissue sample from the placenta (Figure 1 
b)(Mantzaris and Cram, 2015).   Albeit having a high sensitivity and accuracy, both these 
procedures pose considerable risk to the fetus and is conducted at stages of pregnancy where the 
parents may have limited options.  Hence, to fully harness the potential of prenatal diagnosis to 
our advantage, it is crucial to develop a non-invasive technique, where fetal cells can be obtained 
2 
 
from the mother without posing a risk to fetus.  An understanding of prenatal development will 
provide us insights on fetal cell collection with no risks.   
 
a)    b)   c)  
1.1.2 Prenatal Development 
The development of the fetus starts with the formation of an ovum when a sperm fertilizes with a 
zygote in the fallopian tube of the uterus. The ovum rapidly divides and grows to a 16-cell morula 
in the fallopian tube and then to a 32-cell blastocyst which enters the endometrial cavity and 
eventually implants into the endometrial wall of the mother. The outer cells of the blastocyst 
differentiate into trophoblast cells which form the outer layer of the cell while the inner cell mass 
develops into an embryo (Red-Horse et al., 2004). The trophoblast cells invade the decidualized 
endometrium and further divide into two layers called syncytiotrophoblast cells (outer layer) and 
cytotrophoblast cells (inner layer). Once the embryo is completely implanted in the endometrial 
wall, the syncytiotrophoblast cells come in contact with maternal blood and initiate the formation 
of the placenta, which provides the essential nutrients and oxygen to the embryo from the maternal 
blood circulation.   From week 4 of prenatal development, the placenta becomes the primary source 
of nutritional exchange (Figure 1c). The placenta is connected to the embryo through the umbilical 
Figure 1: Schematic of a) Amniocentesis and b) Chorionic Villus Sampling c) Placenta and Trophoblast cells 
interface 
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cord. The maternal portion of the placenta forms the deepest layer of the endometrium. The 
embryonic portion of the placenta is formed by the syncytiotrophoblast cells and cytotrophoblast 
cells which proliferate to form the chorionic membrane. The chorionic membrane forms finger 
like structures that penetrate into the endometrium wall that are called the chorionic villi. The 
cytotrophoblast cells perforate the chorionic villi and into the endometrium to reorganize the 
maternal blood vessels and augment the blood supply around the villi. The placentation is complete 
by weeks 14-16 (Hui, 2012).  This is the period when the trophoblast cells are most proliferative 
and penetrative. Once, the placenta develops into a fully developed organ, it regulates the 
nutritional, respirational and endocrine functions of the embryo. The excreted products and waste 
blood from the fetus travel through the umbilical arteries and the maternal nutrients and oxygen 
travel through the umbilical vein. In the following weeks, the fetus develops the central nervous 
system and the organogenesis of the embryo is completed. 
The prenatal development process highlights that the primary areas of contact between the embryo 
and the maternal circulation is i) through the invasion of the trophoblast cells in the endometrium 
wall in the uterus and ii) the transfer (exchange) of nutrients and cells via blood through the 
placenta and umbilical arteries. Trophoblast cells are shed into the uterine region of the mother 
during the implantation process and can be recovered either from cervical or vaginal area of the 
mother (Fritz et al., 2015). The placenta transfers the excretion and other products through the 
umbilical arteries to the maternal circulation. Hence, traces of cell free fetal DNA can be found in 
the maternal blood circulation. Trophoblast cells and cell free fetal DNA are sources that can 
provide critical information on fetus and are currently being explored for developing non-invasive 
prenatal diagnosis. Trophoblast cells have certain advantages over cell free fetal DNA in that the 
concentration of cells in uterine region is higher than the amount of cell free fetal DNA in blood. 
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According to some reports there are approximately 1 trophoblast cells in 2000 mother’s 
cells(Bolnick et al., 2014) while the concentration of cell free fetal DNA is about 1 in 100,000 
(Bolnick et al., 2014). In addition, the intact cell can be analyzed by a wide range of techniques 
including Immunohistochemistry (IHC), Fluorescent in situ Hybridization (FISH), Fluorescence 
Microscopy, PCR and Genotyping and DNA sequencing. The cost associated with analyzing a 
whole cell can be adjusted according to the analysis method which makes whole cell analysis a 
more flexible and cost-effective method of analysis. 
1.1.3 Trophoblast cells for Prenatal Testing  
Trophoblast cells play a significant role in the fetal implantation into the endometrium wall and 
hence can be found into the uterine region of the mother (Tarrade et al., 2001). Trophoblast cells 
have attracted attention from scientists in the past decade because of their invasive nature and their 
presence in the uterine tissue.  Some scientists have reported that trophoblast cells extracted during 
the early pregnancy harbor important genetic information about the fetus (Mantzaris et al, 2015)   
It was hypothesized that since extra villous trophoblast cells the uterine tissue, some of the 
trophoblast cells will shed in to the uterine region of the mother. These trophoblast cells can be 
sampled from the uterine region (cervix) of the mother and if selectively extracted would provide 
details about genetic information on fetus.  The uterine region comprises of primarily mother’s 
epithelial cells and mucus.  The trophoblast cells are sparsely populated in the areas. In order to 
collect trophoblast cells, they need to be enriched from the mother’s cells by using unique surface 
markers expressed by trophoblast cells.  
The Trophoblast cells shed into the uterine region can be collected through the cervical or vaginal 
region. The trophoblast cells are in a pool of mother’s epithelial cells and are sparsely populated. 
Hence it is crucial to enrich the trophoblast cells from the mother’s cells and extract genetic 
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information from them.   There are several reports in literature about the use of trophoblast cells 
obtained from the cervix for non-invasive prenatal testing that include detection of trisomies 18 
and 21, Rh status of fetal status and hemoglobinopathies (Fritz et al, 2015) (Bolnick et al, 2014).  
Several procedures have been used for isolation of trophoblast cells from the cervical canal and 
one of them is utilization of monoclonal antibodies that are specific to surface markers 
overexpressed on trophoblast cells.  (A. N. Imudia et al., 2009) (Bolnick et al., 2014; Douglas & 
King, 1989; Li & Schust, 2015). 
1.1.4 Cell Surface markers and monoclonal antibodies for Trophoblast cell isolation: 
The most commonly studied surface markers of extra villous cytotrophoblast cells are βHCG (beta 
human chorionic gonadotropin), HLA-G (Human Leukocyte antigen-G), CK7 (Cytokeratin 7) and 
HPL (Human Placental lactogen) (Li & Schust, 2015). βHCG and HPL are proteins that are 
excreted by trophoblast cells to signal the corpus luteum to not dissolve the endometrial wall so 
that the fetus can implant into the endometrial wall. Extra villous cytotrophoblast cells express less 
βHCG as compared to syncytiotrophoblast cells. HLA-G is major histocompatibility (MHC) 
antigen that reacts with maternal Natural Killer cells and inhibits them there by helping the fetal 
cells to escape the maternal immune surveillance system. (Xiaoming Zhu, Han, Yin, Wang, & 
Yao, 2011). HLA MHC complex has other isoforms called HLA-A, HLA-B, HLA-C which are 
not known to be expressed in trophoblast cells.  HLA-G molecule may be transmembrane or 
soluble isoform.  The monoclonal antibodies against HLA-G are developed based on the denatured 
or conformational isoform of HLA-G. The MEM-G9 antibody is made against the conformational 
dependent and transmembrane isoform of the HLA-G. It does not cross react with HLA-A, HLA-
B and HLA-C transfectants. The 4H84 antibody is made against the denatured and soluble isoform 
of HLA-G. It cross reacts with the HLA-A transfectant (Apps, Gardner, & Moffett, 2008).  
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Cytokeratin-7 is a protein encoded by keratin gene which is responsible for the transitional nature 
of the cells.  HLAG is a surface receptor protein and is specifically expressed in trophoblast cells, 
which can be utilized to isolate the trophoblast cells from the epithelial cells (Zhu et al, 2011) (Jain 
et al., 2016).  βHCG and CK7 are primarily used for counterstaining to confirm the isolation of 
trophoblast cells (Bolnick et al., 2014; Anthony N. Imudia, Kumar, Diamond, DeCherney, & 
Armant, 2010). 
1.1.5    Enrichment of Trophoblast cells for Prenatal Diagnosis:  Challenges 
The prenatal diagnosis using trophoblast cells is sought with a few challenges, the primary ones 
being the site of collection, trophoblast cell enrichment and gestational age of the fetus at the time 
of collection.  The current sampling method is focused on collecting cells from cervical canal of 
the mother using a cytological brush which is like a Pap smear test (Mantzaris, 2015). The cervical 
canal has a higher mucus content and is also more susceptible to bleeding from cytological brush 
causing discomfort during sampling. The cells and mucus move into the vaginal area from the 
cervix which can be collected using a cotton swab. The cervicovaginal mucus is essentially diluted 
cervical mucus which make collection and separation of cells easier. Vaginal sample collection 
seldom contain blood and is a relatively easy procedure causing less discomfort and pain in 
patients.   Copan FLOQ™ swabs, made of nylon are optimized to keep the sample closer to the 
surface for fast and complete elution. They have a higher recovery rate than cotton swabs 
(http://www.copanusa.com/products/collection-transport/floqswabs-flocked-swabs//i-love-
floqswabs).   Most of the maternal sample comprises of mucus and the mother’s epithelial cells. 
The trophoblast cells are sparsely populated (1 in 2000) in vaginal and cervical samples (Bolnick 
et al, 2015). The major challenge in extracting the trophoblast cells is to enrich them by separating 
them from the maternal contaminants.   
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Enrichment of trophoblast cells adopted by several groups broadly fall into two categories (1) size 
based separation and (2) surface receptor based separation.  The most commonly used size based 
separation techniques are gradient centrifugation and fluorescent activated cell sorting 
(FACS)((Kavanagh, Kersaudy-Kerhoas, Dhariwal, & Desmulliez, 2010). These techniques suffer 
from certain limitations like clogging, slow separation, low purity, cell loss and damage (Kavanagh 
et al, 2010). In surface receptor based techniques, cells that expressing specific cell surface 
antigens (Kavanagh et al, 2010) are targeted using monoclonal antibodies. The trophoblasts cells 
can be marked by either labelling the antibodies against the cell surface maeker like HLA-G or 
CK-7 with fluorophores or isolated using nanoparticles (Douglas et al, 88) (Li et al, 2015) 
(Stenqvist et al,2008).Nanoparticles have high surface to volume ratio leading to higher binding 
capacity and higher capture efficiency (Wen et al, 2014). In order to obtain genetic information 
from the DNA or chromosome of the trophoblast cells, it is crucial to isolate and extract intact 
trophoblast cells.  Magnetic nanoparticles have unique magnetic properties, wherein they develop 
magnetic moment when placed under an external magnetic field and can be used to magnetically 
separate the cells tagged with the nanoparticles. (Pankhurst, Connolly, Jones, & Dobson, 2003) 
1.1.6 Hypothesis and Solution 
Our hypothesis is trophoblast cells are present in vaginal region along with maternal epithelial cells and can 
be selectively enriched from the pool of mother’s epithelial cells using magnetic nanoparticles 
surface conjugated with monoclonal antibodies specific to HLAG. Magnetic nanoparticles have 
unique properties wherein they develop a magnetic moment when placed under an external 
magnetic field (Gupta et al, 2005). Magnetic particles tagged with antibodies against specific target 
can be isolated using external magnetic force.(Xu & Sun, 2009) Monoclonal antibodies are 
preferred to target specific isotopes of the antigen.(Nelson et al., 2000) Monoclonal antibodies 
against HLA-G conjugated with magnetic nanoparticles can be used to isolate trophoblast cells 
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from the vaginal swab. Trophoblast cells invade the decidualized endometrium into maternal 
uterine region during the first 4 weeks to initiate the formation of placenta. By week 12 the 
formation of the placenta and the chorionic villi is complete (Hui, 2012). The trophoblast cells are 
most active and invasive during the first 12 weeks of the pregnancy. Hence these cells can be 
collected from the uterine region during the first trimester of pregnancy(Ji et al., 2013).Trophoblast 
cells can be primarily found in the cervical or vaginal region of the mother (Imudia et al, 2010). 
The cervical region is amenable to bleeding and thicker mucus. The cervicovaginal fluid is diluted 
cervical mucus (Heng et al., 2015). The vaginal area is less amenable to bleeding and samples can 
be collected through a Coppan Floq nylon swab. To this effect, we made a magnetic nanoparticle 
based enrichment platform to isolate trophoblast cells from a vaginal swab sample collected from 
pregnant women who are in the first trimester of pregnancy.  
 
 
a) b)   
 
 
1.1.7 Magnetic Nanoparticles for Trophoblast Isolation and Enrichment: 
In the past few decades, nanoparticles have been explored extensively in the medical industry for 
applications in diagnostic, therapeutic and theranostic fields. Nanoparticles have core diameters 
Figure 2: a) Au@Fe nanoparticle b) FeNC 
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ranging from 10nm- 40 nm which is comparable to the nuclear pore size and are much smaller 
than a cell ( 10-100µm) (Frey, Peng, Cheng, & Sun, 2009).  Magnetic nanoparticles of a very small 
size form a single magnetic domain. When they are tagged with a target agent, they can interact 
specifically with the biomoclules of interest, which makes them easy to manipulate and target 
(Frey et al, 2009) In most magnetic particles, the external magnetic field (H) and magnetization of 
particle (B) are related as following: 
B=µH, where μ is the magnetic permeability of the particles.  In super paramagnetic particles at 
TB, the hysteresis loop is very narrow, which implies that a there is very less retention of 
magnetism once the external magnetic field is removed (Gupta A, 2005). The high saturation 
magnetization and a low saturation field of the nanoparticles along with no remnant magnetization 
make it ideal for its application in the biological systems. Super paramagnetic particles have less 
inter-particle interactions and hence they will not aggregate amongst themselves and can be 
injected as a ferrofluid or be utilized as a bio sensor for different purposes (Gupta A, 2005). We 
have developed a library of magnetic nanoparticles and investigated their potential in trophoblast 
cell extraction.   The two groups of nanoparticles synthesized were spherical and cubic magnetic 
oxide nanoparticles (Figure 2 a, 2 b).  The spherical iron oxide nanoparticles were further 
functionalized by coating with Gold (Figure 2 b). The nanoparticles were conjugated with different 
antibodies. Our repertoire of magnetic nanoparticles is listed in Table 1.    
Nanoparticles  Properties  
FeNC- 4H84 Iron oxide nanocubes conjugated with anti-HLAG 
antibody (4H84) 
FeNC-MEMG9 Iron oxide nanocubes conjugated with anti-HLAG 
antibody (MEM-G9) 
FeNC-4H84-MEM G9 Iron oxide nanocubes conjugated with anti-HLAG 
antibody( 4H84 and MEM-G9) 
Au@Fe-4H84 Gold coated ironoxide nanospheres conjugated with anti-
HLAG antibody( 4H84) 
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Au@Fe-MEM G9 Gold coated Iron oxide nanospheres conjugated with anti-
HLAG antibody( MEM-G9) 
Au@Fe-4H84-MEM G9 Gold coated Iron oxide nanospheres conjugated with anti-
HLAG antibody( 4H84 and MEM-G9) 
 
1.1.8 Iron oxide Nanocubes (Fe-NC) 
Current technologies used in isolating cells involve the use of large magnetic beads. 
Limitations of these beads include large size (>100 nm) and tendency to aggregate. 
Specifically, magnetic beads are ferromagnetic in nature and have inherent magnetic properties 
and can result in aggregation. These properties lead to low specificity and magnetic capture 
ability. To overcome this limitation, we designed 20 nm magnetic nanocubes with greater 
magnetic moment and paramagnetic properties compared to the magnetic beads. Therefore, 
these nanoparticles do not contain residual magnetization in absence of an externally applied 
magnetic field for capturing them. As they are devoid of inherent magnetization, these particles 
do not agglomerate and achieve high solvent stability. Additionally, the cubic shape has larger 
surface to volume ratio, and higher force of attraction per given angle as compared to spherical 
beads. Iron oxide nanocubes have been reported to have high magnetic moment which leads to 
faster separation kinetics (Zhen et al., 2011).  
1.1.9 Gold Coated Iron Oxide Nanoparticles 
Multifunctional nanoparticles exhibit diverse optical, catalytic, magnetic and physical properties.  
Metal coated iron oxide nanoparticles which have the advantage of getting less aggregated and can 
introduce different functional groups on the surface. Gold conjugated Iron oxide nanoparticles 
(Au@Fe) have unique surface chemistry that enables the nanoparticles to be functionalized easily 
and excellent optical properties due to the gold coating (Pariti et al, 2014). The iron oxide core 
provides the Au@Fe nanoparticles with superparamagnetic properties (Pariti et al, 2014). Gold 
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coated iron oxide nanoparticles offer several advantages. They offer size controllability and can 
be easily manipulated by an external magnetic field due to their magnetic properties hence making 
them very good tools for target selectivity for diagnostics and targeted drug delivery for 
therapeutics. Due to the high surface to volume ratio of the nanoparticles, they have increased 
affinity towards biomolecules and are highly efficient tools for isolating target molecules from a 
pool of nonspecific cells. These properties of the Au@Fe nanoparticles have been utilized in the 
project for selective isolation of trophoblast cells from swab samples collected from the mother’s 
uterine region.  
 
1.2 Materials and Methods 
1.2.1 Materials 
Iron (III) acetylacetonate, Ironn(III) chloride, oleic acid,N-(3-Dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC), N-Hydroxysulfosuccinimide sodium salt (sulfo-
NHS), 2-(N-morpholino)ethanesulfonic acid (MES), bovine serum albumin, MS-SAFE 
Protease and Phosphatase Inhibitor, triton X-100, tween-20 and phosphate buffer saline were 
purchased from Sigma-Aldrich. Hexane, toulene and chloroform were purchased from Acros 
organics. Sodium hydroxide (NaOH), acetone, sucrose, sodium borate buffer, Hoechst dye, 
Cell mask deep red membrane dye, Pierce ECL Western Blotting Substrate, Pierce BCA 
Protein Assay Kit and TMB were purchased from Thermo-Fisher Scientific. Β-Actin, both 
anti-mouse and anti-rabbit secondary HRP-linked IgG antibody were purchased from Cell 
Signaling. Anti-HLAG antibody (4H84) was purchased from BD Biosciences. Anti-HLAG 
antibody (MEM G9), Anti-βHCG antibody was purchased from abCAM. Carboxymethyl-
polyethyleneglycol-thiol was custom synthesized from Nanocs and Laysan Bio. 10x TBS, 10x 
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Tris/Glycine/SDS buffer, 4-15% 10-well 50 µl ready Mini-Protean TGX, Precision Plus 
Protein Dual color standard ladder and supported nitrocellulose Membrane (0.2 µm) were 
purchased from Biorad. Recombinant Human EGF (carrier-free) and Alexa Fluor 647 anti-
Cytokeratin PAN antibody were purchased from BioLegend. Amicon 0.5 ml 100Kd 
Regenerated cellulose Ultracel centrifugal filter units were purchased from Merck Millipore 
Ltd.  
 
1.2.2 Instrumentation 
Core nanoparticle size measurements were performed using Joel TEM. Hydrodynamic size and 
zeta potential was measured using a Malvern Zetasaizer Nano-ZS. Centrifugation was 
performed on a 5424 Eppendorf and refrigerated RC 6+ Sorvall centrifuge. pH was measured 
using a Seven Compact Mettler Toledo pH meter equipped with an InLab Micro electrode. 
Fluorescence imaging, fluorescence assays and UV-vis absorption assays were performed on 
a Cytation 5 Cell imaging multi-mode reader. Gel electrophoresis was performed on a Biorad 
Mini-Protean Tetra system and blots were transferred using a Genscript e-blot transfer system. 
Western blot imaging and acquisition was performed using Image Lab ver 5.2.1 software on a 
ChemiDoc XRS system from Biorad. Band densitometry analysis was performed on Image 
Studio ver 5.2. Solvent extraction was performed on a Büchi Rotovapor R-124 attached to a 
water bath and watercoo led distillation column. SQUID measurements were performed on a 
Quantum Design MPMS 3 Magnetometer. 
1.2.3 Synthesis of Iron oxide nanocubes (FeNC) 
The synthesis was carried out under an argon atmosphere using standard Schlenk line techniques. 
In a typical synthesis of magnetite nanocubes (79nm), iron acetylacetonate (7.06g, 20mmol) was 
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added to a mixture of oleic acid (1.129g, 12.689ml) and benzyl ether (104g, 99.71ml) (Zhen et 
al,2011). The mixture was degassed under argon at room temperature for 30 minutes. The solution 
was then heated to 290oC at the rate of 20oC/min with vigorous magnetic stirring. The reaction 
mixture was maintained at this temperature under argon atmosphere for 30 minutes. After cooling 
the solution to room temperature, a mixture of toluene (40ml) and hexane (10ml) was added to the 
solution. The solution was then centrifuged at 10,000g for 20 minutes to precipitate the magnetic 
nanocubes. The separated precipitate was washed again with hexane and toluene till a clear 
supernatant was obtained. The final pellet was dissolved in hexane. Iron nanocubes synthesized 
using polyol process resulted in formation of hydrophobic particles soluble only in organic 
phase. In order to convert them to hydrophilic particles for use in aqueous and physiological 
solutions, we replaced the organic coating with a functional amphiphilic polymer by modifying 
a previously published protocol(Teng & Yang, 2004).  
Briefly, synthesized FeNCs (in hexane) were injected into a rapidly stirring (500 RPM) Poly 
(maleic anhydride-alt-1-octadecene) (1.2 g, mol wt. 30,000-50,000) solution dissolved in 
chloroform (100 ml) in a one neck 200 ml round bottom flask. After 2 h of stirring, solvent 
was removed using a rotary evaporator (100 RPM, 55 °C) attached to standard vacuum line 
protected by a liquid nitrogen cool trap, until a wet sludge was formed. The sludge was quickly 
mixed with 50 ml of 0.1 M NaOH solution and dispersed using sonication for 1 h. Solution 
was then stirred (500 rpm) for 15 h at room temperature to hydrolyze and open the maleic 
anhydride rings. The opening of these rings adds free carboxylic groups to the ends of the 
polymer. These groups can be used to functionalize amines on the nanoparticle surface by –
COOH activation. The solution was washed 2 times with 0.1 M NaOH solution at 20,000 g (15 
°C) for 1 h, followed by 2 times with 3-layer sucrose density gradient centrifugation (30%, 
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20% and 10% sucrose). Pellet was resuspended and concentrated in 4 ml 10 mM MES buffer 
and washed once. As a next step 100 kDa centrifugal filters were equilibrated with MES buffer 
and used for removing excess polymer (6000g for 6 min). Solution was then again subject to 
2-layer sucrose density gradient centrifugation (30% and 10% sucrose) at 15000g for 15 min, 
followed by washes with DI water. FeNC pellet was then redispersed in 5 ml water and stored 
at room temperature. 
1.2.4 Synthesis of Au@Fe nanoparticles 
Au@Fe NPs were synthesized using a two-step process. First, iron oxide nanospheres were 
synthesized by thermal decomposition of iron oleate complex. The second step comprised of 
reduction of gold (III) ions on iron oxide nanospheres to form Au@Fe nanoparticles. The FeNC 
NP were synthesized using a polyol synthesis method which involves thermal decomposition of 
the iron oleate complex to form iron oxide nanoparticles (Zhen et al, 2011). The iron oleate 
complex was prepared using a previously established method with a few modifications(Park et al., 
2004). Briefly, 4.8gm NaOH was dissolved in 50ml DI water to which 80ml Ethanol and 40ml 
oleic acid was added slowly and the pH was adjusted to 7. 10.8gm FeCl3 was dissolved in 10ml 
DI water and added to the oleic acid solution along with 140ml hexane. The solution was heated 
to 60oC and maintained at the temperature for 4 hours. The upper organic layer containing the iron 
oleate complex was washed with 30ml DI water three times. The excess hexane was removed with 
rotary vacuum evaporator at 65oC for one hour resulting in a dark red waxy solid iron oleate 
complex. Spherical iron oxide nanoparticles were synthesized by adding 7.2gm iron oleate 
complex to 50.69ml 1 octadecene and 1.28 ml oleic acid. The iron oleate mixture was 
deoxygenated under nitrogen atmosphere for 20 minutes. The solution was heated to 300oC at a 
heating rate of 5oC/min and maintained at the temperature for 30 minutes after which the heating 
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source was removed and the solution was allowed to cool to room temperature. The resulting dark 
brown solution was precipitated using 100ml acetone. The precipitated particles were washed with 
hexane and acetone three time at 15000g for 30 minutes. The final pellet was dissolved in 5ml 
Chloroform.  The Au@Fe nanoparticles were synthesized by a previously established procedure 
with significant modifications (Robinson, Tung le, Maenosono, Walti, & Thanh, 2010). Iron oxide 
nanoparticles (0.9gm) were dissolved in 10ml octadecene and 1.3 gm 1, 2 hexadecanediol. The 
solution was heated to 100oC for 1 hour and subsequently heated to 140oC to which gold 
oleylamine complex was added. The complex was prepared by sonicating HAuCl4 in 5ml 
octadecene and 1 ml oleylamine. The iron oxide solution with the gold complex was heated at 
140oC for 15 minutes followed by heating to 200oC. The solution was maintained at the 
temperature for 20 minutes and then removed from heat to be cooled to room temperature. The 
nanoparticles thus formed were hydrophobic particles soluble only in organic phase. In order to 
convert them to hydrophilic particles for use in aqueous and physiological solutions, we 
replaced the organic coating with a functional amphiphilic polymer by modifying a previously 
published protocol(Robinson et al., 2010). 
1.2.5 Antibody conjugation to Au@Fe and FeNC particles 
The polymer coated iron oxide nanocubes were covalently conjugated to antibody (anti-HLAG) 
via standard EDC/NHS activation chemistry (Zhang et al., 2014) (Nakajima & Ikada, 1995).  We 
followed manufacturer’s protocol for the EDC and NHS activation. Briefly, 100l(mg/ml) of PMA 
coated FeNCs and PEG coated Au@Fe nanoparticles were washed with MES buffer prior to being 
activated with 3mg EDC and 4mg NHS in 400µl MES buffer at 28oC for 3.5 hours. The activated 
particles were centrifuged at 15,000g for 12 minutes. The supernatant was discarded and the 
activated FeNC and Au@Fe pellet was dissolved in 20l Anti-HLAG (4H84) antibody (0.5mg/ml) 
16 
 
and 200 µl 1X PBS and incubated overnight at in a thermomixer at 24oC and 750 rpm. The 
antibody conjugated particles were centrifuged at 15,000g for 12 minutes and re-suspended in 1ml 
1X PBS. The particles were stored in 4oC. Similar procedure was repeated for conjugation of 
Au@Fe and Fe NC nanoparticles with 10l anti- HLAG (MEM G9) antibody (1mg/ml) and 200µl 
1X PBS.  For the conjugation of both anti-HLAG (4H84 and MEM G9) epitopes, the activated 
Au@Fe and FeNC nanoparticles were dissolved in 20µl anti-HLAG (4H84) and 10µl anti-HLAG 
(MEM G9) and 200µl 1X PBS and incubated overnight at 24oC in a thermoshaker. The Au@Fe 
and FeNC nanoparticles were conjugated with the secondary antibodies anti-Mouse IgG and anti-
Human IgG using similar process as described above. The activated Au@Fe and FeNC 
nanoparticles were dissolved in 20l anti-Mouse IgG (3mg/ml) and 60µl anti-Human IgG 
(1mg/ml) and 200µl 1X PBS.  
1.2.6 Target binding Affinity by ELISA 
The conjugation of the antibody to the nanoparticle was confirmed utilizing a surrogate antigen 
(Globin), and anti-Globin antibody as the surrogate antibody. Briefly, 100µl of Globin solution at 
different concentrations (100µg/ml, 10µg/ml, 1µg/ml, 0.1µg/ml, 0.01µg/ml and 0.001µg/ml) was 
added to each well of a 96 well plate and incubated overnight at 4oC. The wells were washed with 
wash buffer (0.5% Tween20) followed by blocking with 200µl 2% BSA solution for 30 minutes 
at Room temperature. The wells were washed with wash buffer prior to addition of 100µl antibody 
conjugated nanoparticles. Nanoparticles without antibody were used as a negative control while 
antibody solution was used as a positive control. In all the experiments PBS was considered as the 
blank. The nanoparticles were incubated for 2 hours at 37oC followed by washing the wells once 
with wash buffer. 50µl of 0.32µg/ml Secondary antibody (goat anti Rabbit IgG) conjugated with 
Horse-radish Peroxidase (HRP) was added to the wells and incubated for 30 minutes at 37oC 
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followed by washing the wells twice with wash buffer. Finally, 50l of the substrate (TMB 
peroxidase) was added to the wells and the reaction was stopped by adding 0.1M HCl solution. 
The plates were read by a Cytation plate reader at absorbance of 450nm.  
1.2.18 Cell Studies 
Jeg 3 cells were obtained from ATCC. SKBr3 cells, obtained from ATCC were used as negative 
control. All the cells were cultured in RPMI-1640 medium (ATCC, modified with 4500mg/ml 
Glucose) with 1% Fetal Bovine Serum (Atlanta Biological, Sigma Aldrich) and 700ul Gentamycin. 
Cells were grown in a CO2 incubator (Thermo Fisher) with 5% CO2 and 37oC.  
1.2.8Clinical Samples   
Trophoblast cells were isolated from discarded placental tissues after obtaining consent, non-
pregnant women vaginal swab samples collected from healthy volunteers, vaginal swab samples 
and cheek swab samples from pregnant women during the first trimester of pregnancy were used 
for the study.    The study was approved by University of Missouri, Columbia (IRB no. 2002862) 
review board.  A total of 16 placenta of a male fetus was obtained.    Trophoblast cells were 
extracted by enzyme digestion of the placental tissue followed by Percol density gradient 
centrifugation ((Li & Schust, 2015). The trophoblast cells were stored in DMEM media at 4oC.  
A total of 45 vaginal swab samples were collected from pregnant women with gestation age 
ranging from 5 to 12 weeks.   Vaginal swab samples from both pregnant and non-pregnant women 
were obtained using FLOq Coppan™ swabs. The swabs were stored in DMEM medium in 4oC.  
Swab samples collected from pregnant women were stored in DMEM media and cells were 
extracted by centrifuging at 2000rpm for 10 minutes at RT. The centrifugation was repeated till a 
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noticeable cell pellet was formed. The cell pellet was then washed with serum free media three 
times to remove mucous and used for trophoblast enrichment studies.  
1.2.19 Western Blot analysis of HLA-G expression:  
Trophoblast cells harvested from human placental tissues and Jeg3 cells (106 cells/ml) were seeded 
in a 6 well plate overnight. Whole cell lysates were prepared using Triton X 100 lysis buffer with 
MS-Safe protease and phosphatase cocktail inhibitor (Sigma Aldrich) and protein concentration 
was equalized with Bicinchoninic acid assay (Sigma Aldrich). Proteins were separated by 4-15% 
native PAGE (Bio-Rad) and were transferred onto nitrocellulose membranes (Gen Script). The 
membranes were incubated with Primary antibody overnight at 4oC. The primary antibodies used 
for this experiment are β HCG, anti HLAG (4H84) and anti HLAG (MEM G9). The antibodies 
were washed and then incubated with secondary anti Mouse IgG HRP or anti rabbit IgG-HRP and 
incubated for 2 hours at 37oC. The membranes were washed and imaged on Chemidoc Biorad 
imaging system. Actin protein levels were used as a control for adequacy of equal protein loading. 
Protein expression levels were analyzed by densitometry analysis. 
1.2.20 Flow Cytometry analysis of HLA-G expression 
Trophoblast and Jeg3 cells (105 cells/ml) were incubated with primary antibodies (anti HLAG 
4H84, anti HLAG MEMG9) for 1 hour at RT and washed a few times with staining buffer. The 
cells were then incubated with anti-Mouse IgG Alexa Fluor 488 for 1 hour at RT. The cells were 
washed few times with staining buffer and fixed with 4% PFA. The cells were analyzed through 
FACs caliber for percentage expression of HLAG and MEMG9 in Jeg3 and trophoblast cells. 
1.2.21 Magnetic capture Efficiency of MNPs 
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The magnetic capture efficiency of the Au@Fe and FeNC was determined using a surrogate 
antigen (globin and antibody (anti-globin). 500ul of globin solution at different concentrations 
(100µg/ml, 50µg/ml and 25µg/ml) were taken in an Eppendorf tube. 200µl of Au@Fe-anti globin 
antibody (anti-globin Ab) was added to the solutions and incubated at room temperature (RT) for 
different time durations (0 hour, 3 hours, 12 hours). Au@Fe-Peg at the same concentration was 
used as control. Following incubation, the tubes were kept in front of a neodymium (N52) block 
magnet for 20 minutes. The supernatant was removed and stored. The pellet was dissolved in 500ul 
1X PBS and kept in front of magnet for 20 minutes. The supernatant was removed and stored, and 
the final pellet was dissolved in 500µl 1X PBS. The UV-Vis absorbance spectrum of the 
supernatants and pellet was recorded using a UV-Vis plate reader in Cytation 3. 
1.2.22 Cell Capture Efficiency of MNPs 
Following the proof of principle studies with surrogate antibody and antigen, we proceeded 
to conduct magnetic capture experiments by using Au@Fe-HLAG (4H84) and FeNC-HLAG 
(4H84). Jeg3 cells (105cells/ml, 104 cells/ml) was stained with membrane staining red dye 
followed by incubation with Au@Fe-HLAG and FeNC-HLAG for 2 hours at 37oC. Au@Fe-
Peg and FeNC-Peg were used as controls. Following incubation with magnetic nanoparticles, 
the solution were kept in front of a neodymium block magnet for 20 minutes. The supernatant 
was removed and 1X PBS was added to the cell pellet. The magnetic washing was repeated 
two times. The cells were finally suspended in 200 µl serum free media and imaged under the 
fluorescence with Cytation 5 and were analyzed with Cytation 5 cell analysis software. 
1.2.23 Cell Capture Specificity of MNP 
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The specificity of the cells was determined by capturing target cells (Jeg3 cells) from a mix 
of Jeg3 and SkBr3 cells. Epithelial cells extracted from vaginal swab of non-pregnant women 
was used as a negative control. The Jeg 3 cells were stained with red membrane dye C10446 
and the epithelial cells were stained with nucleus staining dye Hoechst 3342. Jeg3 cells of 
varied concentration were (10,100, 1000 cells/ml) were mixed with SkBr3 or epithelial cells 
(100,000, 10,000 cells/ml) and incubated with antibody conjugated magnetic particles 
(Au@Fe-HLAG, FeNC-HLAG) for 2 hours at 37oC. Following incubation, the cell solution 
was kept in front of a NeodymiumN 52 block magnet for 20 minutes. The magnetic 
nanoparticles formed a pellet near the magnet. The supernatant was removed and the pellet 
was dissolved in 200ul 1X PBS. Magnetic separation was repeated twice and the pellet 
obtained was dissolved in 1X PBS and transferred to a 96 well plate. The plate was analyzed 
with Microplate reader (Cytation 3). The cells were counted using cytation analysis software. 
1.2.24 Cell Capture Selectivity for Trophoblast cells 
For the clinical samples, the efficiency of the magnetic nanoparticles in capturing trophoblast 
cells was confirmed using two different methods. The first one was based on direct 
conjugation, where anti-HLA-G antibody was conjugated with the magnetic nanoparticles 
and were incubated with the cells followed by magnetic separation. The second method was 
the HLA-G saturation method, where the magnetic nanoparticles were conjugated with a 
secondary IgG antibody. The cells were incubated and saturated with anti HLA-G antibody 
at 37oC for two hours followed by incubation with Au@Fe-IgG or Fe-IgG nanoparticles at 
37oC for 2 hours. The cells were then magnetically separated and washed and analyzed using 
Fluorescence imaging and lysed to extract DNA for sequencing and analysis studies.  
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Direct Incubation Method:  Trophoblast cells were mixed with epithelial cells obtained from non-
pregnant women vaginal swab samples.  s in different ratios (1: 1000 (0.01%) and 1:100 (0.1%)).  
10, 100 cells were mixed with 104 epithelial cells and 100, 1000 cells were mixed with 105 cells/ml 
epithelial cells. The trophoblast cells were stained with membrane staining C10446 dye (red) while 
the epithelial cells from non-pregnant women were stained with nucleus staining Hoechst 3342 
dye (Blue).  The cell mixture was incubated with nanoparticles (Au@Fe and FeNC) conjugated 
with the HLAG antibody for 2 hours at 37oC followed by magnetic separation two times. The 
pellet was dissolved in DIW and transferred to a 96 well plate for imaging and analysis with 
Cytation 5 plate reader. 
HLA-G Saturation Method:  The cell capture experiment was repeated with HLA-G saturation 
method. Briefly, pre-stained trophoblast (C10446) and non-pregnant swab cells (Hoechst 3342) 
were mixed together in different ratios. The cell suspension was incubated with 20µl anti-HLAG 
(4H84) antibody (0.5 mg/ml) and 10µl anti-HLAG (MEM G9) antibody (1 mg/ml) at 37oC for 2 
hours. The cells were then incubated with 200ul Au@Fe-IgG or Fe-IgG nanoparticles at 37oC for 
2 hours. The cells were then placed in front of a magnet for 30 minutes and the supernatant was 
removed. The pellet was dissolved in Serum free media and the magnetic washing step was 
repeated 3 more times. The cells were then transferred to a 96 well plate and imaged and analyzed 
using Cytation 5 microplate reader 
1.2.25 DNA Analysis 
DNA was extracted from the isolated trophoblast cells using ethanol precipitation and 
resolubilization. DNA obtained was quantified by Qiagen Investigator Kit using RT PCR. 
Briefly, 1ng of template DNA was amplified using Promega PowerPlex Fusion kit and the 
22 
 
fragments are visualized using capillary electrophoresis on 3130 XL for STR analysis. Gene 
Mapper ID was used for data analysis (PTC Laboratories, Columbia) 
1.2.26 Cell capture with swab cells from pregnant women 
The cells isolated from pregnant women were used for trophoblast enrichment by both direct 
incubation and HLAG saturation procedures as described in detail in section 1.2.14. The isolated 
cells were stained with DAPI nucleus staining dye followed by counter staining with β HCG 
conjugated dye.  The cells were imaged and analyzed using Cytation 5. Cells were also analyzed 
using HLA-G saturation method. Cells were extracted from the swab samples by centrifuging at 
2000g for 7 minutes three times.  For fluorescence imaging and trophoblast cell confirmation by 
βHCG staining, the cells were incubated with β HCG-Cy5 for 1 hour at 37oC. 10µg anti-HLA-G 
(4H84) and 10µg anti-HLA-G (MEM-G9) was added and incubated at 37oC for 2 hours followed 
by incubation with 250µl of AF-IgG or 150µl Fe-IgG at 37oC for 2 hours. The cells were 
magnetically separated and washed four times. The cells were then transferred to a 96 well plate 
and they were imaged using Cytation 5 microscope.  
1.2.27 Immunohistochemistry staining with CK 7 
 To confirm whether the cells extracted by magnetic nanoparticles were trophoblast cells, the cells 
were coated on a microscope slide by cytospin and stained with anti-CK 7 antibody and imaged 
under the microscope. 150l of the Cells solution (12,000cells/ml) were spun at 700 rpm for 5 
minutes onto positive charged slides and air dried for 2 hours to overnight. The slides were then 
fixed in formalin (10% NBF) for 10-20 minutes and rinsed in water. Slides were treated with Dako 
Target retrieval solution Citrate buffer and heated at 95oC for 20 minutes in a steamer followed by 
cooling to RT for 20 minute sand rinsing with DIW and incubated with 1X PBS for 5 minutes. 
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The step was repeated twice. Blocking was done by Normal Horse Serum. The cells were 
incubated with anti-Cytokeratin 7 (Oy-TL 12/30) mouse monoclonal antibody (Cell Marque, 
307M-95, 25g/ml) with 1:200 dilution in Ventana antibody diluent.  The slides were then 
incubated in MOM ImmPRESS Reagent (Anti mouse IgG polymer reagent peroxidase) for 30 
minutes and then washed two times in buffer.  The chromagen peroxidase substrate was then added 
to the cells dropwise and the sections were washed in deionized water. Counterstaining was done 
by adding Hemotoxylin staining solution and incubating for 1 minute followed by rinsing with 
water. The cell slides were then dipped in 95% alcohol, 100% alcohol and xylene 10 times and 
were allowed to harden overnight. The slides were imaged under the Leica Microscope and were 
analyzed by a Pathologist.  
1.3 Results and Discussion 
1.3.1 Synthesis and Characterization of FeNC and Au@Fe Nanoparticles 
Iron oxide nanocubes (Fe NC) and Gold conjugated iron oxide nanospheres (Au@Fe) were 
synthesized by thermal decomposition of iron acetylacetonate and iron oleate complex respectively 
(Park et al., 2004) ( Robinson et al,2010) (Clara et al,2012)( Figure 3). 
 
Figure 3 Schematic of synthesis of Iron oxide nanocubes (FeNC) 
oIron oxide nanospheres were coated with gold layer to form a core shell structure using oleic acid 
and oleylamine (Robinson et al) (Figure 4). 
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Figure 4 Schematic of synthesis of Gold coated Iron oxide nanoparticles (Au@Fe) 
 
 The resulting hydrophilic Au@Fe and FeNC particles had a hydrodynamic size of 156nm, 200nm 
and Zeta potential of -20 mV and -15mV respectively. TEM images of the iron oxide nanocubes 
(Figure 5a) and spherical nanoparticle (Figure 5b) confirm that the particles are uniform with a 
core size of 20nm and core diameter of 30 nm respectively UV-Vis absorbance of 540 nm). 
 
a)    b)  
 
HR TEM images show the distinct lattice structure of the nanoparticles. Energy dispersive X-ray 
spectroscopy analysis of the Au@Fe nanoparticles demonstrate the presence of both Au and Fe in 
a single nanoparticle (Figure 6). 
Figure 5: a) TEM Image of Fe Nanocubes b) TEM Image and UV Absorbance of Au@Fe Nanoparticle. 
25 
 
        
 
The magnetic properties of the nanoparticle were determined by a SQUID Magnetometer. The 
close hysteresis curve demonstrates that the particles are paramagnetic in nature (Figure 7).  The 
magnetic nanospheres have a near saturation magnetization value of 4.5 emu/g while the magnetic 
nanocubes have a magnetization of 45 emu/g. The magnetic nanocubes and nanospheres were 
functionalized using Peg OME and Thiol-Peg-SH respectively to introduce COOH functional 
groups to the nanoparticles. 
  
 
Figure 6: EDS analysis and HR TEM Images of Au@Fe Nanoparticles 
Figure 7: Hysteresis loop of Fe3O4 nanospheres, Au@Fe nanoparticles and Fe Nanocubes (FeNC).
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1.3.2 Synthesis and Characterization of Au@Fe-Ab and FeNC-Ab nanoparticles:  
Anti-HLAG antibody or Anti mouse IgG was covalently conjugated to the nanoparticles. The 
antibody conjugation was confirmed by comparing the size and zeta potential of the antibody 
conjugated Au@Fe (Table 2) and FeNC nanoparticles (Table 3) with their precursors. The UV-
Vis absorbance of the Au@Fe broadened upon conjugation with antibody(Figure 9).    Bradford 
assay and Micro drop assay was used to determine the antibody conjugation efficiency. Both the 
methods confirmed conjugation efficiency of 70%.  
Figure 8: ZFC curves of Fe3O4 and Au@Fe Nanoparticles                                                          .
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Table 2: UV absorbance peak, Hydrodynamic size and Zeta Potential of Au@Fe nanoparticles
Table 3: Hydrodynamic size and Zeta Potential of Fe nanocubes 
Figure 9: UV-Vis absorbance graph of Au@Fe, Au@Fe-Peg and Au@Fe-Antibody
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The ability of antibody conjugated magnetic nanoparticles to capture target antigen  was validated 
using a surrogate antigen and antibody. We chose hemoglobin   as our target antigen and anti-
globin antibody was the target binding efficiency between the nanoparticle-antibody conjugate and 
antigen was validated by traditional ELISA procedures.  Globin solution at different concentrations 
was coated on a 96 well plate and then incubated with nanoparticles conjugated with anti-Globin 
Antibody. Anti-globin antibody was used as a positive control, while Au@Fe-PEG was used a 
negative control. Physical mixture of Au@Fe-PEG and anti-globin antibody was used as another 
positive control.  The binding efficiency of Au@Fe-Gb was found to be tenfold higher than 
Au@Fe-PEG and about 1.5 times more than globin antibody itself(Figure 10 a). The binding 
efficiency of Au@Fe-Ab was almost 1.25 times higher than Au@Fe-PEG and Ab physical mixture 
at higher concentrations of Globin.   From the ELISA graphs, it was established that the detection 
limit of Globin using Au@Fe-Gb is around 0.100 ng/ml (Figure 10 b). However, the detection 
efficiency increased with increasing globin concentration 100g/ml with Au@Fe-Gb. 
 
1.3.3 Target Binding by ELISA 
Figure 10: a) Binding affinity of Au@Fe-Gb and Globin at different concentrationsof Globin (g/ml) compared to 
control. b)  Comparison of binding affinities of Au@Fe-Gb with Au@Fe and GbPhysical mixture at different 
concentrations (ng/ml) 
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The magnetic capture efficiency of the Au@Fe and Fe nanoparticles was determined using a 
surrogate antigen and antibody.  Au@Fe-anti-globin Ab was incubated with different 
concentrations of Globin solution followed by magnetic separation (Figure 11) and the time of 
incubation was optimized by incubating at three different time points. Globin has absorbance peak 
at 410nm. The UV-Vis absorbance of the pellet and supernatant obtained after magnetic separation 
was recorded at 410 nm to estimate the amount globin that was bound to the nanoparticle.  
 
 
Different concentrations of globin (100µg/ml, 50µg/ml and 25μg/ml) were incubated with 
Au@Fe-anti globin Ab at RT for 3 hours and 12 hours. Au@Fe-Peg was used as control.  The 
absorbance peak corresponding to globin at 410  Were recorded and correlated to capture 
efficiency.  No globin peaks were observed for Au@Fe solution. The amount of globin extracted 
by the nanoparticles (Au@Fe) was quantified by estimating the amount of globin present in the 
supernatant (Figure 12). The optimized time for globin capture was calculated to be 3 hours (Figure 
13 b). Based on the extracted amount of globin in the pellet the efficiency of Au@Fe-anti globin 
Ab was estimated as 40-50% for globin solution  at a concentration of 25ug/ml and 50ug/ml ( 
Figure 13 a).  
Figure 11: Schematic of the magnetic capture process of Globin using magnetic nanoparticles
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a)    b)  
1.3.4 Antibody selection for trophoblast isolation 
HLA-G expression of the Jeg 3 and trophoblast cells extracted from the placental tissue was 
confirmed using western blot and Flow cytometry analysis. There are different antibodies against 
HLA-G based on the isoform (denatured and conformational) of HLA-G. The two commonly used 
HLA-G antibody epitopes that are reported in literature were 4H84 and MEM-G9 (Apps et al., 
2008) . 4H84 is made against the denatured isoform while the MEM-G9 is against the 
Figure 12: a) UV-Vis absorbance of Globin solutions at different concentrations b) UV-vis absorbance of 
                    Magnetically separated pellet of Au@Fe-anti globin Ab and Au@Fe-Peg 
Figure 13: a) Globin capture efficiency of Au@Fe-anti Globin Ab at varying Globin concentrations 
b) Globin capture efficiency of Au@Fe-anti Globin Ab from 50µg/ml solution at different time points 
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transmembrane isoform. Western blot and Flow cytometry experiments were conducted with both 
MEM-G9 and 4H84 epitopes as well as βHCG antibody. MEM-G9 expression in both Jeg3 and 
trophoblast cells was found to be 3 folds higher than 4H84 expression (Figure 14). Comparable 
results were reflected from flow cytometry experiments. βHCG expression was found to be higher 
in Jeg3 as compared to trophoblast cells (Figure 15). Both the isoforms of anti-HLAG antibody 
(4H84 and MEM G9) individually and as a combination were used to target the trophoblast cells 
by conjugating the antibodies with magnetic nanoparticles (Au@Fe and Fe NC). Anti-βHCG 
antibody was used for counterstaining in Fluorescence imaging applications. 
 
  
 
 
 
Figure 14: Western Blot images of expression of HLA-G (4H84), HLA-G (MEM-G9), β HCG and analysis of images 
Figure 15: Flow cytometry analysis of 4H84 and MEM G9 expression of trophoblast cells 
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1.3.5 Magnetic Cell Capture Efficiency of Nanoparticles 
To determine the capture efficiency of Au@Fe-Ab and FeNC-Ab nanoparticles, Jeg3 cells 
(105cells/ml) were stained with a nuclear staining Hoechst 3342 dye and incubated with anti-
HLAG antibody at 37oC for two hours. Magnetic nanoparticles (Au@Fe and FeNC) without 
antibody were used as control. Prior to cell capture efficiency, the amount of antibody to be 
conjugated to the nanoparticles for maximum capture efficiency of the JEG-3 cells was optimized 
by using magnetic nanoparticles prepared with different concentrations of HLA-G antibody.    
(Figure 16). From the optimization experiments it was determined that 20g (0.5mg/ml HLAG) 
of the antibody is required for   optimal (~75%) capture efficiency.   The capturing efficiency of 
both MNPs were determined by fluorescence imaging (Figure 17). The magnetic nanospheres 
captured the target cells with an efficiency of 75% whereas the magnetic nanocubes captured the 
target cells with a target efficiency of 70% (Figure 18).  
 
a)  b)  
 
 
Figure 16: Optimization of antibody conjugation for a) Au@Fe Nanoparticles and b) Fe Nanocubes 
33 
 
 
 
 
 
1.3.6 Cell Capture Specificity with JEG 3 
The selectivity of the Au@Fe-Ab and FeNC-Ab nanoparticles was determined using a mixture of 
JEG-3 cells that overexpress HLA-G with SKBR-3 cells that have minimal or no HLAG 
expression.  Typically, these two cells were mixed at a ratio of 1:1and incubated with Au@Fe-
Figure 17: Fluorescent Images of Jeg3 cells captured with magnetic nanoparticles with and without antibody 
Figure 18: Number of cells captured from a pool of 104 and 105 Jeg3 cells by magnetic nanoparticles 
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4H84 and FeNC-4H84 antibody for 2 hours followed by magnetic washing and imaging under 
fluorescence microscope. The Jeg3 cells were stained with membrane staining C10446 dye while 
the SkBr3 cells were stained with nuclear staining Hoechst 3342 dye. The specificity of MNPS to 
isolated JEG-3 cells was determined by fluorescence imaging.    MNPs were capable of isolating 
65% of Jeg3 cells was 65% compared to  2.5%, of SKBR-3 confirming the preferential capture of   
MNPs  JEG-3 over SKBr-3 cells  (Figure 19 b).  
  
The specificity of MNPS were tested with Jeg3 cells spiked in a pool of epithelial cells obtained 
from the swab sample of non-pregnant women.  Jeg 3 cells of varying concentrations were spiked 
in a constant pool of in epithelial cells (104 cells) and were incubated with anti-HLAG-4H84-MEM 
G9 conjugated Au@Fe nanoparticles (Figure 20). The capture efficiency of the nanoparticles was 
around 70% for 10 cells spiked in 10,000 nonspecific cells. The capture efficiency decreased with 
increasing number of Jeg 3 cells suggesting that at higher concentrations of Jeg 3 the cell capture 
efficiency of the nanoparticles reached a saturation point. 
Figure 19: Cell capture efficiency of the magnetic nanoparticles in pool of 104 cells/ml SKBr3 and Jeg3 cells of varying 
concentrations 
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  β HCG-Cy5 staining and fluorescent imaging was performed on the cells pre-stained with 
Hoechst 3342 after separation with Au@Fe and FeNc nanoparticles.  The fluorescent images 
confirmed the capturing efficiency and specificity of Au@Fe nanoparticles  to isolate JEG-3 cells 
(Figure 21).  
 
1.3.7 Magnetic Cell Capture of trophoblast cells 
Following the promising results with Jeg3 cells we investigated the efficacy of the magnetic 
particles in capturing trophoblast cells from a pool of epithelial cells. We used a mixture of 
trophoblast cells isolated from discarded placenta and epithelial cells isolated from non-pregnant 
Figure 20: Cell capture efficiency of the magnetic nanoparticles in pool of 104 cells/ml VS and Jeg3 cells of varying 
concentrations 
Figure 21: Fluorescent imaging of the β HCG staining of Jeg3 and Non pregnant VS cells 
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women vaginal swab samples.   We   spiked trophoblast cells at different concentrations (1:1, 
1:10.1:100 and 1:1000)with epithelial cells obtained from a swab sample of non-pregnant 
women. The trophoblast cells were stained with C10446 dye (Red) and the non-pregnant vaginal 
swab samples were stained with Hoechst 3342 (Blue) dye   The cells were incubated with Fe-
HLAG and Au@Fe-HLAG separately at 37oC for two hours followed by magnetic isolation and 
washing.  We conducted magnetic separation experiment with Au@Fe-MEM G9-4H84 and 
FeNC-MEM G9-4H84 conjugates.  The extraction efficiency for the trophoblast cells was 
determined by fluorescence imaging.  The imaging results showed that the efficiency as around 
70% for 1:1 and 1:10 ratios for both Au@Fe- MEM G9-4H84 and FeNC- MEM G9-4H84 
conjugates. The individual and overlayed fluorescent images are shown in (Figure 22). For lower 
ratios (1:100, 1:1000) the extraction efficiency increased to 85%. (Figure 23). The cell capture 
efficiency of the Au@Fe- MEM G9-4H84 and FeNC- MEM G9-4H84 conjugates were 
compared with the cell capture efficiency of Au@Fe-4H84 and FeNC-4H84 conjugates. Au@Fe-
4H84-MEM G9 conjugate demonstrated a capture efficiency of 85% while Au@Fe-4H84 
conjugate demonstrated a capture efficiency of 60% (Figure 24). FeNC-4H84-MEM G9 
conjugate demonstrated a capture efficiency of 75% while FeNC-4H84 conjugate demonstrated a 
capture efficiency of 45% (Figure 24). From the above experiments, Au@Fe-4H84-MEM G9 
and Fe NC-4H84-MEM G9 were selected as the candidate nanoparticles for further trophoblast 
cell isolation and capture experiments and for clinical studies with swab samples from pregnant 
women. 
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a)      b)  
 
Figure 23: Cell capture efficiency of the magnetic nanoparticles in capturing trophoblast cells of varying concentration 
from a pool of epithelial cells (Non Pregnant vaginal swab cells) b) Cell capture efficiency of magnetic nanoparticles from 
TP and VS cells in 1:1 (104TP: 104VS) and 1:10 (103TP: 104VS) ratio 
Figure 22: Fluorescent Images of trophoblast cells spiked in VS cells in 1:10 ratio before and after magnetic separation 
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1.3.8 DNA Analysis 
To confirm the capture of trophoblast cells from the pool of epithelial cells, the DNA from the 
magnetically isolated cells were extracted and amplified using RT PCR with X and Y chromosome 
specific primers and electropherogram was recorded.   DNA was obtained for sequencing from the 
cells before and after magnetic separation. Since the trophoblast cells are from a male placenta the 
trophoblast cells are expected to show both X and Y allele while the epithelial cells isolated from 
non-pregnant women should show only X alleles. In a sample with trophoblast and mother’s cells 
mixed in a ratio of 1:10, the Y allele will be significantly less. However, in cells obtained following 
magnetic separation, the Y allele peak should be at least two fold higher compared to the original 
swab sample. The peak ratios of the X and Y allele show that there has been 50-65% enrichment 
in the trophoblast cells   fluorescence imaging studies.  The electropherogram recorded for the 
samples isolated by MNPS are shown in (Figure 25).  
Figure 24: Cell capture efficiency of the Au@Fe and FeNC magnetic nanoparticles conjugated with 4H84 and 4H84-MEM 
G9 from a pool of TP cells and NP VS 
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The DNA analysis of the isolated trophoblast cells demonstrated a cell capture efficiency of 50% 
for trophoblast cells spiked in VS cells in 1:1 (Figure 25 a) and 1:10 (Figure 25 b) ratios. We 
performed the DNA analysis experiments for 10 trophoblast cell and 10 Non pregnant VS cell 
samples.  The cell capture efficiency demonstrated with fluorescent analysis was not translated 
DNA analysis results. From previous DNA analysis experiments, it was established that an 
enrichment of   1:8 (80%) is preferred for clinical purpose.  
We conducted the magnetic separation studies with trophoblast cells spiked with epithelial cells 
by HLAG saturation experiment to explore whether higher capture efficiencies were obtained. 
Figure 25 a): Electropherogram Images of Trophoblast cells spiked in VS in 1:10 ratio before and after magnetic separation. 
Figure 25 b): Electropherogram Images of Trophoblast cells spiked in VS in 1:1 ratio before and after magnetic separation.
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Trophoblast cells were mixed in varying ratios with VS cells and were incubated (saturated) with 
anti HLAG antibodies (4H84 and MEM-G9) for 2 hours. Following incubation, Au@Fe-IgG or 
Fe-IgG nanoparticles were added and incubated for 2 hours. The cells were then imaged under 
fluorescence microscope and analyzed with Cytation 5 software. Fe NC-IgG conjugate 
demonstrated a cell capture efficiency of 75% while AF-IgG demonstrated a cell capture efficiency 
of 60% (Figure 26 a). The trophoblast to VS cell capture ratio was calculated for Au@Fe-IgG and 
FeNC-IgG conjugates and compared with that of Au@Fe-4H84-MEM G9 and Fe-4H84 -MEM 
G9 conjugates (Figure 26 b). The trophpblast to VS cell capture ratio was 10:1 for Fe NC-IgG 
conjugate, while the ratio was 8:1 for Au@Fe-IgG conjugates which was two times higher than 
that of Au@Fe-4H84-MEM G9 and Fe NC-4H84-MEM G9 conjugates. 
a)  b)  
 
The isolated cells were treated with DNAse and lysed to extract DNA for DNA quantification and 
subsequent DNA amplification with PCR for X and Y chromosomes. The ratio of the X and Y 
peak for isolated cells was 75% of the original mixture suggesting that there has been a 75% 
enrichment in the isolated cells (Figure 28).  The use of saturation procedures increased the 
enrichment to 90%.     (Figure 27).  
Figure 26: a) Cell capture efficiency of magnetic nanoparticles with HLAG saturation method b) The trophoblast/VS capture ratio 
of Au@Fe and Fe nanoparticles with HLAG saturation and direct conjugation method.
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1.3.9 Isolation of Trophoblast cells in pregnant women samples 
Encouraged by the positive results from the simulation studies, experiments were conducted on 
vaginal swab samples collected from pregnant women (5-12 weeks). A total of 45 Swab samples 
were collected from the Missouri OB/GYN Associates (MOBA) at the University of Missouri. 
The presence of trophoblast cells in the vaginal swab sample was confirmed by IHC analysis with 
Figure 27: Fluorescent images of the trophoblast and VS cells mixed in 1:10 ratio before and after separation
Figure 28: Electropherogram Images of Trophoblast cells spiked in VS in 1:10 ratio before and after magnetic 
separation with HLAG saturation method 
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CK 7. CK 7 is a specific trophoblast cell marker and is commercially available for IHC staining. 
The cells slides were analyzed under the microscope by a pathologist. We conducted IHC 
experiments with CK7 antibody on three swab samples prior to magnetic separation to confirm the 
presence of the trophoblast cells in the swab samples (Figure 29). We confirmed that there were 1 
trophoblast cell for every 1000-1500 epithelial cells in the swab sample.  
 
 
The swab samples were then separated using Au@Fe-4H84-MEM G9 and FeNC-4H84-MEM G9 
using and washed. Immunohistochemistry was performed on the isolated cells using anti-CK-7 
antibody.  A lot of cellular debris was observed.  The cellular debris may be due to the isolation of 
cells using FeNC particles that had higher magnetic moment compared to Au@Fe (Figure 30). We 
repeated the isolation with less powerful magnet and noticed less celluar debris   
 
 
Figure 29 IHC stain images of cells from swab sample from pregnant women before magnetic separation 
Figure 30 IHC stain images of cells from swab sample from pregnant women after magnetic separation 
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Trophoblast isolation efficiency was explored using the AuFe-4H84-MEM G9 (direct isolation 
method) and HLAG saturation method. The isolated cells were stained with nucleus staining 
Hoechst 3342 dye (Blue) and were then counterstained with β HCG-Cy5 (Red). The counter 
stained cells were imaged and analyzed using Cytation 5. The first 8 samples were analyzed using 
direct isolation method while the rest of the 10 samples were analyzed using the HLAG saturation 
method (Figure 31 a). The average cell number was around 1100 cells in a sample of 3*106 cells/ml 
(Figure 31 b) which was comparable to the trophoblast cell count isolated from cervical samples 
(Fritz et al, 2015) (Bolnick et al, 2014). We observed from our initial fluorescence studies that the 
trophoblast cell count of the vaginal swab samples obtained from pregnant women with 5-12 
weeks of gestation age was comparable to cervical swab samples collected from pregnant women 
(Bolnick et al, 2014). 
a)   b)  
 
DNA analysis:  DNA was extracted from the isolated trophoblast cells to demonstrate that even 
after magnetic separation, the trophoblast cells remained intact and genetic information could be 
extracted from them. 12 swab samples were collected and trophoblast cells were isolated using 
Direct conjugation method with FeNC-IgG nanoparticles. DNA was extracted from the isolated 
cells using ethanol precipitation and quantified using Qiagen Investigator kit. According to the 
trophoblast cell count obtained from IHC experiments and from literature reports (Bolnick et al, 
Figure 31 a) Trophoblast cell count of individual samples b) Average cell count of all the samples. 
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2014) (Fritz et al, 2015).  The average total cell count from the swab varied from 1*106 cells/ml – 
3*106 cells/ml.  It has been reported in literature that each cell contributes approximately 6.5 
picograms of DNA (Georgiou & Papapostolou, 2006). Extrapolating from the above calculations, 
we can extrapolate that the amount of trophoblast DNA extracted from the vaginal swab samples 
will vary from 1 ng to 4 ng depending on the number of total cells in the sample. It was observed 
from the DNA quantification experiments, that individual DNA amount varied in each sample 
(Figure 32 a), however the average DNA count was around 3.5ng (Figure 32 b) which was 
comparable to our theoretically calculated value. To confirm whether the DNA extracted was from 
trophoblast cells, short tandem repeat (STR) sequencing was performed on the amplified DNA 
extracted from the trophoblast cells. Out of the 8 samples, three samples were lost to bacterial 
contamination. The remaining samples were analyzed with genetic analyzer.   A male profile was 
obtained from two samples possibly suggesting that the DNA extracted is that from a male fetus 
(Figure 33). A female profile was obtained from the two other samples, possibly suggesting that 
the DNA extracted was from a female fetus 
a)   b)   
 
Figure 32 a) DNA quantification of individual samples b) Average DNA quantification for all the samples. 
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1.4 Conclusion:                                                                                                                                   
We hypothesized that trophoblast cells can be selectively isolated from the vaginal swab of the 
pregnant woman in the first trimester of pregnancy using magnetic nanoparticles surface 
conjugated with monoclonal antibodies specific to surface receptors present on the trophoblast 
cells.  We synthesized Au@Fe and Fe NC nanoparticles and then conjugated them with anti-
HLAG antibodies as well as IgG. Two different epitopes of HLA-G antibody were used for the 
experiments (4H84 and MEM G9). For maximum selection efficiency, we conjugated both the 
epitopes, MEM G9 and 4H84 to the Au@Fe and Fe NC.  The target binding affinity and 
capturing efficiency of the MNPs were confirmed using  surrogate antigen and anti- Globin 
antibody (anti-Globin Ab) as the target antibody. The experiments proved that Au@Fe-anti 
Globin Ab and Fe NC-anti Globin Ab can capture target antigen with a detection range of 0.1- 
100ug/ml. We then conducted target binding studies with human choricarcinoma (Jeg3) and 
breast cancer (SKBr3) cells to determine the sensitivity and selectivity of the magnetic 
nanoparticles. The Au@Fe-4H84 and Fe Nc-4H84 nanoparticles demonstrated a capture 
efficiency of 75%. We then conducted clinical studies to test whether magnetic nanoparticles 
can selectively isolate trophoblast cells from a pool of epithelial cells. Trophoblast cells were 
Figure 33 Electropherogram image of the extracted DNA shows a male profile suggesting the DNA could be from a male 
fetus 
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extracted from placental tissues of male fetus and spiked in epithelial cells obtained from the 
vaginal swab obtained from non-pregnant women. Two different extraction methods were 
used, direct incubation and HLA-G saturation. The isolated cells were imaged under 
fluorescence and DNA was extracted to amplify them using PCR and were analyzed using 
STR sequencing. The capture efficiency of direct conjugation method was around 65-70% 
according to fluorescence images. DNA analysis also demonstrated a 50-65% enrichment of 
the trophoblast cells.  Capture efficiency of HLA-G saturation method was around 75-80% 
according to fluorescent images, DNA analysis demonstrated a 75% enrichment of the 
trophoblast cells. We then conducted clinical studies on samples on swab samples collected 
from pregnant women in the first trimester of pregnancy. Cells were isolated using direct 
conjugation and HLA-G saturation methods. The cells were stained with βHCG-Cy5 and 
analyzed under fluorescent microscope. Immunocytochemistry    with CD10 and CK7 
antibodies was conducted on the extracted trophoblast cells. According to IHC analysis there 
were approximately 1 trophoblast cell in every 2000 epithelial cells (Bolnick et al, 2014). The 
cells were enriched after magnetic separation. DNA was extracted from the isolated cells and 
the amplified and quantified using PCR. The amount of DNA extracted corroborated with the 
theoretical analysis. Some samples were contaminated by bacteria and DNA was degraded due 
to environmental factors. 
 A male profile was obtained from the extracted DNA from some of the samples suggesting that 
the DNA could be from the male fetus. Thus, in conclusion, we have demonstrated that magnetic 
nanoparticles can extract trophoblast cells from a sample (less than 12 weeks GA) with around 
75% efficiency. 
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We developed a library of magnetic nanoparticles and proved that they could be utilized to 
capture target cells from a pool of non-specific cells in clinical settings with 75% to 80% 
efficiency. Further Optimization is required to increase the capture efficiency and to reduce 
entrapment of the nanoparticles in excess mucus.  
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CHAPTER 2 
NANOPARTICLE BASED ASSAY FOR SCREENING RETINOPATHY OF 
PREMATURITY (ROP) 
2.1 Introduction 
2.1.1 Retinopathy of Prematurity (ROP) 
Retinopathy of Prematurity (ROP) is a retinal vascular disease which causes disrupted retinal 
blood vessel growth in premature infants born before 32 weeks of gestation or weighing under 
1500gm (Ates et al., 2009).  ROP inhibits the retinal neuronal and vascular development in the 
preterm infant that results in aberrant vascularization of the retina. ROP is one of the leading 
causes of blindness among infants and children(Chen & Smith, 2007). According to the National 
Eye Institute, out of the 3.9 million babies born every year, around 14,000-16,000 are expected 
to develop ROP of varying severity. It is estimated that approximately 10% of the infants with 
ROP will develop stage 3 or higher ROP which often leads to retinal detachment or blindness 
(Hellstoerm et al, 2013).  
2.1.2 Clinical Diagnosis and Challenges  
 The current diagnostic procedure for ROP involves a physical fundus exam of premature infants 
who are at higher risk of developing ROP. In this procedure, the dilated eye of the infant is 
examined by an ophthalmologist using an ophthalmoscope to detect the vascular damages in the 
retina of the infant.  The major risk factors of the ROP are the gestational age at birth (less than 
32 weeks) and very low birth weight (less than 1500 gm).  
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The results are grouped in three categories: Normal retina, immature retinal vasculature and 
ROP. ROP is characterized by location of proliferation (Zone) and the severity of vascular 
damage (Stage) and the presence of circuitous (tortuous) blood vessels in retina. Zones are 
classified as Zone 1, Zone 2 and Zone 3 with zone 1 being a circular disc including the center of 
vision of the infant. Zone 2 is concentrically outside of zone 1 where it extends to Ora serrata. 
Zone III is the remaining temporal crescent of the retina(Asano et al,2014) (Figure 34). 
 
ROP is graded as different stages; stage 1 is determined by a demarcation line formed by blood 
vessel at the avascular junction of retina. If the blood vessels proliferate further they gain depth 
and height and form ridge like structure, it is categorized as stage 2 ROP. In stage 3, the blood 
vessels grow further vertically into the vitreous plane and forms a mat or cord of blood vessels 
(Asano et al, 2014). The mat like structure may cause scar formation due to contractile element 
which creates tension along the retinal and vitreous surfaces leading to semi retinal detachment 
(Stage 4) or complete retinal detachment (Stage 5) (Figure 34).  Stage 5 ROP may lead to 
complete blindness.   The fundus photographs of different stages of ROP is shown in Figure (35). 
Figure 34 The different zones of an embryonic retina to determine the ROP status 
54 
 
 
                                            Figure 35: Fundus Photograph of various stages of ROP 
Timely screening of premature born infants who are at a higher risk of developing ROP is a 
valuable tool in controlling the incidence of ROP. However, so far, the diagnosis and screening 
technique for ROP is the same which involves a physical eye examination by the 
ophthalmologist by dilating the eye of the infant. The first examination is performed by 31-week 
postmenstrual age or by 4 weeks chronologic age, with additional examinations performed 
repeatedly thereafter to detect late stage ROP requiring treatment. The physical examination 
process also involves subjecting the infant to a bright source of light for the ophthalmologist to 
be able to examine the various zones. This analysis method is very subjective, and the results are 
prone to changing based on the doctor examining the eye. In addition, the procedure is very 
discomforting for the infant and parents to be used as a screening technique.  Therefore, it is thus 
very crucial to identify a biomarker that can be associated with the onset of ROP. The biomarker 
can be used to develop a non-invasive screening tool to screen infants who are at a higher risk of 
developing ROP without causing them any discomfort. 
2.1.3 Pathogenesis of ROP  
ROP is characterized by two phases of development. During the first phase, which takes place 
till 30-32 weeks of post menstrual age, the vessel growth in the retina is disrupted. Infants who 
are born at this phase have an incompletely vascularized retina.  These preterm babies are 
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generally exposed to elevated oxygen levels in the incubator resulting in hyperoxia condition 
which downregulates the Vascular Endothelial Growth Factor (VEGF) and there is recession of 
growth vessels.  The second phase of ROP is characterized by uncontrolled growth of the blood 
vessels or angiogenesis induced by hypoxia. When the infants are out of the incubator, they 
experience a relative hypoxia which stimulates growth factors like VEGF  and erythropoietin 
that lead to uncontrolled blood vessel (vascular) growth in the vitreous leading to 
neovascularization (Chen, Stahl, Hellstrom, & Smith, 2011) (Figure 36) .  
a)       b)  
Figure 36: a) Molecular pathways in Phase 1 ROP b) Pathways in Phase 2 ROP 
Both disrupted blood vessel growth and uncontrolled angiogenesis lead to an increased 
production of ROS which causes oxidative stress in the cells. Oxidative damage disrupts 
biomolecules like proteins and DNA (Ates et al, 2009). ROS causes the DNA strand breaks and 
base modifications. The most common base modification is the oxidation of the guanine base in 
the DNA forming 8-hydroxy 2-deoxyguanosine (8-OHdG) (Ates et al, 2009).  
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2.1.4 Hypothesis and Solution 
8-OHdG is formed by oxidation of guanine base in DNA as a result of enzymatic cleavage. The 
amount of urinary 8-OHdG reflects the amount of oxidative damage occurring in the body 
(Hinokio et al, 2004).  We hypothesized that 8-OHDG can be considered as a useful biomarker 
for determining the level of oxidative stress caused due to retinal damage. These oxidized DNA 
products are water soluble and are excreted through the urine without undergoing further 
metabolism.  Our hypothesis was that 8-OHdG will be excreted in urine and can be identified 
easily. We hypothesized that levels of 8-OHDG in patients with ROP will be higher than in 
patients without ROP.    
The most commonly used analytical techniques for the detection for 8-OHdG are high-
performance liquid chromatography-electrochemical detection (HPLC-ED), HPLC tandem mass 
spectrometry, gas chromatography-mass spectrophotometry (GC-MS), Capillary Electrophoresis 
with electrochemical detection (CE-ECD). These techniques have good sensitivity and accuracy; 
however, these are lab based techniques requiring expensive instrumentation and trained 
personnel.  Enzyme Linked Immunoassay (ELISA) is also used for the colorimetric detection of 
8-OHdG. 8-OHdG is a small molecule, hence the major challenge is to immobilize it for the 
purposes of capture and detection. The most common method for detection of 8-OHdG is by 
conjugating it with a heavy protein like BSA (Bovine Serum Albumin) and conducting a 
competitive ELISA for the detection and analysis (Wu et al, 2004). Albeit being less complex 
than HPLC techniques, it is still a lab based and time consuming and hence is not suitable for 
bed side or in-house detection of 8-OHdG. For these purposes, there is a need for the 
development of a point-of-care testing device which is portable and has faster readout times. We 
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have developed a Lateral Flow Immunoassay (LFIA), for simple and easy detection of the 
marker.(Hinokio et al., 2002) (X. Zhu, Shah, Stoff, Liu, & Li, 2014).  
2.1.5 Gold Nanoparticles for LFIA  
Gold nanoparticles exhibit unique optical and surface properties which have been widely utilized 
in biological applications like determination of tumor biomarkers, toxins etc. (Wu et al, 2015). 
The advantages of gold nanoparticles are that they are highly biocompatible, easily modified for 
surface functionalization and have low toxicity (Wu et al, 2015). Another important property of 
gold nanoparticles is the induction of Localized surface Plasmon resonance (LSPR) on incidence 
of light. The nanoparticles absorb and scatter light with greater intensity than their bulk material 
counterparts (Anker et al, 2008). This property enables the gold nanoparticles to be used as 
colorimetric labels for immunoassays and other biological applications (Anker et al, 2015) 
(Figure 38).  In this project, gold nanoparticles were used as colorimetric substrates for detection 
of 8-OHdG in paper strip based Lateral Flow Immunoassay. The gold nanoparticles were 
functionalized with anti-8-OHdG antibody using electrostatic binding (Figure 37).  
a)  b)  
 
 
Figure 37 a) Schematic of Gold nanoparticle conjugated with anti-8-OHdG antibody b) Schematic of 
LFIA paper strip
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2.1.6 Substrates of 8-OHdG for ELISA and LFIA  
8-OHdG is a small molecule and its direct immobilization on any surface is challenging. 8-
OHdG must be conjugated with a carrier protein such as BSA (Bovine serum albumin) for 
surface immobilization ((L. L. Wu, Chiou, Chang, & Wu, 2004; X. Zhu et al., 2014).  We have 
conjugated BSA with 8-OHdG by a periodate oxidation method(Xuena Zhu, Hondroulis, Liu, & 
Li, 2013) (Figure 39). The diol groups of the ribose moiety are oxidized to dialdehyde which is 
then conjugated with the amino groups of the amino acid by carbodiimide bond. Competitive 
ELISA was performed to on a 96 well plate to assess the binding affinity of the BSA-OHG 
substrates to the anti-OHdG antibody (Figure 38 a).  From the initial ELISA experiments it was 
observed that BSA-OHG was amenable to being washed away from the plate after several 
washing steps. A library of nanoparticles were prepared including gelatin nanoparticle 
conjugated with BSA-OHG, Latex beads-BSA-OHG conjugates and magnetic nanoparticle-
BSA-OHG conjugates. Initial ELISA studies were conducted with each of the conjugates and it 
was observed that gelatin nanoparticle conjugated with the BSA-OHG was least susceptible to 
washing away from the plates (Figure 38 b). Gelatin nanoparticles formed by two step 
desolvation method with acetone precipitation and crosslinked with glutaraldehyde are very 
robust and versatile nanoparticles that are used for several applications (Naidu & Paulson, 2011). 
Gelatin nanoparticles can be covalently conjugated with antibodies for detection and analysis. 
(Figure 39 a) ELISA studies showed that these nanoparticles are more adherent to the surface as 
compared to the other conjugates Figure 39 b). We chose the Gel-BSA-OHG as the robust 
substrate for all the consecutive ELISA and LFIA experiments for optimization and clinical 
studies.  
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a)     b)  
 
a)  b)  
 
 
We analyzed the samples using Competitive ELISA and Lateral Flow Immunoassay and 
foundthat both the assay results correlated well with the Fundus results. The results were 
correlated with the ROP status of the patients which were determined by physical examination.  
2.2 Materials and Methods 
2.2.1 Materials 
HAuCl4 (Hydrogen Tetraaurochlorate) was purchased from Acros Organics. Bovine Serum 
Albumin (BSA), Sodium Periodate, 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide(EDC) and 
Bicinchonic assay kit were purchased from Sigma Aldrich. Gelatin, Sodium citrate trihydrate, 
Hydroxy sulfo succinimide (Sulfo-NHS) were purchased from Thermo Fisher Scientific. OHG 
Figure 39 a) Schematic of Gel-BSA-OHGconjugate b) Competitive ELISA 
with Gel-BSA-OHG
Figure 38 a) Schematic of BSA-OHG conjugate b)Competitive ELISA on a 96 well plate with BSA-
OHG conjugate
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and 8-OHdG were purchased from Cayman Chemicals. Anti-8-OHdG [15A3] antibody was 
purchased from AbCam. Anti-Mouse IgG-HRP was purchased from Jackson Laboratories. 
Polyethylene Glycol-NHS (PEG-NHS) and succinimidyl PEG-NHS were purchased from 
Nanocs. TMB substrate was purchased from BioRad. The Nitocellulose membrane, the sample 
pad and the conjugate pad were purchased from Millipore. Artificial Urine was purchased from 
QuikFix.  
2.2.2 Instruments 
Core nanoparticle size measurements were performed using Joel TEM. Hydrodynamic size and 
zeta potential was measured using a Malvern Zetasaizer Nano-ZS. Centrifugation was 
performed on a 5424 Eppendorf and refrigerated RC 6+ Sorvall centrifuge. pH was measured 
using a Seven Compact Mettler Toledo pH meter equipped with an InLab Micro electrode. 
Fluorescence imaging, fluorescence assays and UV-vis absorption assays were performed on 
a Cytation 5 Cell imaging multi-mode reader. Gel electrophoresis was performed on a Biorad 
Mini-Protean Tetra system and blots were transferred using a Genscript e-blot transfer system. 
Western blot imaging and acquisition was performed using Image Lab ver 5.2.1 software on a 
ChemiDoc XRS system from Biorad. Band densitometry analysis was performed on Image 
Studio ver 5.2. Solvent extraction was performed on a Büchi Rotovapor R-124 attached to a 
water bath and watercoo led distillation column. SQUID measurements were performed on a 
Quantum Design MPMS 3 Magnetometer. The antibodes and substrate were coated on the 
paper strip using a Camag Linomat 5 automated dispenser.  
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2.2.3 Synthesis of BSA-OHG Conjugates 
BSA-OHG conjugate was synthesized based on a previous publication with some modifications 
(L. L. Wu et al., 2004; Xuena Zhu et al., 2013).  
BSA solution was prepared dissolving 12.5mg BSA in 1 ml of 50mg/ml K2Co3. 8-OHG (0.5 mg) 
was dissolved in 100 µl of periodate and mixed in dark conditions for 1 hour in a thermomixer at 
RT. 200l of BSA was added and mixing was continued for 1 hour in dark followed by addition 
of 200l of NaBH4 (24mg/ml). The solution mixed overnight at 4oC and passed through 10kDa 
filter. Gelatin nanoparticles were synthesized using a two-step desolvation process as described in 
the previous section. BSA-OHG was covalently conjugated with Gelatin nanoparticles using 
EDS/NHS activation method. 1 ml Gelatin nanoparticles (6mg/ml) were centrifuged at 15,000g 
for 12 minutes. The supernatant was discarded and to the pellet 2.4 mg EDC in 3.6 mg of NHS 
were added in 40µl. The volume of the solution was made to 1ml and incubated in thermomixer 
at 24oC for 4 hours. The activated nanoparticles were washed once to remove excess EDC and 
NHS. 36 µl of BSA-OHG in 1 ml 1X PBS was added to the nanoparticles and mixed overnight. 
The BSA-OHG conjugated nanoparticles were washed twice with 1X PBS. The final pellet was 
dissolved in 1X PBS. 
2.2.4 Synthesis of Gold Nanoparticle Conjugates 
The AuNPs were synthesized by a modified citrate reduction method (Afrasiabi et al., 2010). 
Briefly, 50 ml of 0.01% HAuCl4 solution was heated to a boil followed by a rapid addition of 
trisodium citrate solution (1 mL, 1%) under vigorous stirring. After the color changed from yellow 
to red, the solution was continued to boil for another 10 min, then stirred without heating till the 
solution reached the room temperature.  The AuNPs solution was concentrated 10X using a 70KD 
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membrane filter. The pH of the AuNPs solution was adjusted to 8.5 ∼ 9.0 with K2CO3 (0.1 M).  
The optimum concentration of antibody necessary for conjugating the AuNPs to stability is 
determined by a salt based aggregation test. The electrostatically stabilized AuNPs aggregate in 
the presence of salt till the surface is stabilized by enough protein. Briefly, 50 µl of antibody of 
decreasing concentrations (1, 0.5, 0.25, 0.125, 0.0625, 0.03125 mg/ml) were taken in separate 
tubes. They are incubated with 750 ul of 10X AuNPs for 20 mins followed by the addition of 0.5 
ml of 10% NaCl to all of them. 
2.2.5 Competitive ELISA 
A 96 well plate was coated with 100l of GEL-BSA-OHG at different dilutions (1:100, 1:1000, 
1:10000) and incubated overnight at 4oC. The wells were washed with 100l ELISA wash buffer 
followed by blocking with 200l Blocking buffer (2% Milk solution) for 30 minutes. The wells 
were then washed with ELISA wash buffer and 50ul anti 8-OHdG antibody solution (1ug/ml) with 
50l 8-OHdG solution at different concentrations (0.1 mg/ml, 0.01 mg/ml) was added to the wells 
and incubated for 2 hours. Excess of unbound antibody was removed by washing with ELISA 
wash buffer.  50l of Anti-mouse IgG- HRP was then added to the wells and incubated for 30 
minutes. The excess antibodies were washed away and 50l of the colorimetric substrate (TMB) 
was added followed by 50l of stop solution (0.1M HCl). The colorimetric intensity was analyzed 
by measuring their UV absorbance at 450nm.  
2.2.5 Lateral Flow Immunoassay  
We observed that the color of AuNP turned blackish blue and the LSPR peak underwent blue shift 
to all the concentrations below 0.5 mg/ml. The optimal concentration of AuNP at which no 
aggregation is seen was chosen for antibody conjugation.  Thus, 0.5mg/ml is the optimum 
63 
 
concentration of the antibody. To ensure maximum loading of the antibody, the 10X AuNPs (900 
µl) were incubated with 50 μl of 1mg/ml purified anti-8-OHdG Ab at 750 rpm, RT for 1 hour. The 
conjugate was then incubated with BSA (10%) in sodium borate (20 mM) for a final concentration 
of 1% for another 20 min. Then the mixture was centrifuged for 15 min at 7000 rcf. The faint pink 
supernatant of unbound antibodies was discarded, and the pellet was resuspended in BSA/PBS 
(900 μl, 1%) to further wash away any unbound antibodies. Following the same centrifugation 
step, the supernatant was removed, and the soft sediment of conjugates was resuspended in 
conjugate pad buffer (900 μl). 
The conjugate pad, sample pad and absorbent pad were assembled with 1-2 mm overlap on a 6 cm 
x 30.1 cm laminated card with Hi-Flow Plus lateral flow membrane with a 0.19mm backing 
adhered to the surface of the card (HF180MC100 Millipore). Once assembled, Gel-BSA-8OHG 
(1mg/ml) and goat anti-mouse IgG (1mg/ml) were dispensed on the nitrocellulose membrane 
(2l/cm) using a Linomat 5 dispenser as test line and control line respectively. The assembly was 
then dried for 1 hour at 37 °C, cut into 4mm wide strips using a strip cutter and the strips were 
stored in the desiccator at RT. The 4mm wide strips were immersed in 80 ml of standards or urine 
samples in transparent plastic vials. The development of color was seen within 10 min. To 
maximize the color intensity and to maintain uniformity, the photographs of the strips were taken 
90 min after their dip in the standards/samples. The intensity of the color was quantified using 
ImageJ software. 
2.2.6 Analysis of Clinical samples 
The clinical study was approved by the review board in University of Missouri, Columbia (IRB 
No 2004129). Urine samples were collected from collected from preterm infants admitted in the 
Neonatal Intensive Care Unit (NICU) of the Women’s and Children Hospital at University of 
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Missouri, Columbia.  The consent for collecting the samples were taken from the parents of the 
babies. The urine was collected through cotton balls inserted in the diapers of the babies. Samples 
were collected at 24 hours and 72 hours after the birth and then once every week till the baby was 
discharged from the NICU. The ROP status of the babies who qualified for the ROP examination 
or screening was determined after a physical examination of the dilated eye of the baby by an 
ophthalmologist. The qualifying or inclusion criteria for ROP screening of the patients was that 
they are born before 32 weeks of gestation and/or weigh less than 1500 grams. 8-OHdG levels of 
the samples were analyzed using traditional competitive ELISA with Gel-BSA-OHG substrate and 
with Lateral Flow Immunoassay based paper assay with Gold nanoparticle conjugated with anti-
8-OHdG antibody as the colorimetric substrate. Student t-test was conducted on the samples using 
Minitab.  
80l of 8-OHdG solutions of varying concentrations (0, 5, 10, 20, 40, 50 60, 70 ng/ml) were added 
to a quartz cuvette and the paper strip was dipped in the solutions. The color development on the 
test line was observed for the strips within 5 minutes and the test and control lines images were 
captured using a camera. The images were analyzed using ImageJ software and a standard curve 
was obtained by plotting the ratio of the intensity of test line/ nitrocellulose membrane against 
concentration (ng/ml) of 8-OHDG. Urine samples were centrifuged at 3000g. 80ul of the samples 
were added to a quartz cuvette. The color development at the test and control line was captured 
using a smartphone after 1 hour. The intensity of the test line of the urine samples was analyzed 
using ImageJ and the 8-OHdG values were calculated based on the standard curve of known 8-
OHdG values. 
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2.3 Results and Discussion 
2.3.1 Synthesis and Characterization of Gel-BSA-OHG conjugate 
8-OHDG is a small molecule and cannot be immobilized on a substrate or well plate on its own. 
The most common method of immobilization is by conjugating OHG to a carrier protein like 
Bovine Serum Albumin (BSA). OHG was conjugated to BSA using periodate conjugation 
method where the diol groups of ribose moiety of OHG were oxidized to aldehyde by periodate 
and were conjugated to the lysine residues of the BSA. The conjugation of BSA to OHG was 
ascertained by UV-Vis absorption of the BSA-OHG conjugate. The UV-vis absorption spectrum 
of the BSA-OHG was broader compared to that of the unconjugated BSA (Figure 40 a). The 
amount of OHdG conjugated to BSA was estimated using UV-Vis absorption. The conjugation 
efficiency of the OHG to BSA was estimated to be around 33%.  Gelatin nanoparticles were 
conjugated to BSA-OHG using EDC/NHS activation. The core and hydrodynamic size of the 
nanoparticles was around 250 nm (Figure 40 b). The zeta potential of the Gel-BSA-OHG 
nanoparticle was 18 mV. 
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a)      b)  
2.3.2 Synthesis and characterization of Gold Nanoparticle conjugates  
Gold nanoparticles were synthesized by reduction of gold ions using sodium citrate as a reducing 
as well as stabilizing agent. UV-vis absorbance was recorded to confirm the formation of gold 
nanoparticles which exhibit an absorbance peak at 520 nm (Afrasiabi et al., 2010)( Figure  41 b). 
Size and zeta potential measurements were performed.  The hydrodynamic size was found to be 
20 nm, core size of 10 nm using TEM (Figure 41 a) and zeta potential is -19 mV.   
 
Figure 40 a) UV-vis absorbance of OHG and BSA-OHG conjugate b) TEM image of Gel-BSA-OHG nanoparticles 
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a)      b)  
The gold nanoparticles were concentrated to 10X and the pH adjusted to 8. The anti-8 OHdG 
antibody was bound to the negatively charged gold nanoparticles via electrostatic binding. The 
conjugation was followed by blocking with BSA buffer to block the free surfaces of the gold 
antibody conjugate. The optimal amount of antibody to be conjugated with the gold nanoparticle 
by aggregation studies with NaCl. Different concentrations of antibody were added to the gold 
nanoparticle in 10% NaCl solution. At an optimal antibody concentration, no color change would 
be observed  in the gold nanoparticle solution (L. Wu, Pu, Liu, Zhao, & Shu, 2015). We 
observed that when 8µl of anti 8-OhdG antibody (1 mg/ml) was added to AuNp, the 
nanoparticles did not exhibit any color change. (Figure 42), suggesting that 8µg of anti-8-OHdG 
antibody was the optimal amount of antibody to be added. Hence, for all future experiments, 8ul 
of anti-8-OHdG antibody was added to the gold nanoparticle solutions.  
 
Figure 41 a) TEM image of Citrate Gold Np b) UV-vis absorbance of Citrate Gold nanoparticle 
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2.3.3. Competitive ELISA for Detection of 8-OHDG  
Competitive ELISA was performed to evaluate the efficiency of Gel-BSA-OHG to detect OHDG 
in varying concentrations. Gel-BSA-OHG was coated on the plate with varying concentrations 
on a 96 well plate followed by incubation with anti OHDG antibody (1ug/ml) with varying 
concentrations of 8-OHdG.  Addition of Secondary IgG with HRP enzyme and its subsequent 
reaction with the TMB substrate established the varying color intensity of the wells depending on 
the concentration of the Gel-BSA-OHG and OHDG (Figure 43).  The signal intensity decreased 
with increasing 8-OHdG concentrations. 
 
Figure 42 UV-Vis absorbance graph of antibody conjugated citrate AuNP 
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From the ELISA results, we established that Gel-BSA-OHG can be used as a substrate for the 
detection of OHDG at a concentration of 1 mg/ml.  We concluded that GEL-BSA-OHG at a 
concentration of 1 g/ml could be used a robust substrate for the competitive ELISA (Figure 44).  
 
 
Figure 43   Competitive ELISA with anti-OHdG antibody with varying concentrations of 8-OHdG 
Figure 44 Standard curve of Competitive ELISA with anti-8-OHdG antibody with varying concentrations of 8-OHdG 
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The human urine is composed of several components like urea, sodium, potassium, creatinine 
and other dissolved ions. The Gel-BSA-OHG and antibody-nanoparticle conjugate should not 
have any interference with the other components of the urine and should be able to detect only 
the amount of OHDG present in the sample. Artificial urine, which has the similar composition 
as human urine, was purchased from Quikfix.  Competitive ELISA was performed on a 96 well 
plate with Gel-BSA-OHG as the substrate and varying concentrations of OHDG was added to 
the artificial urine sample (AU). The ELISA results demonstrated that the colorimetric intensity 
decreased with increasing OHDG concentrations, validating the utility of the substrate for 
detecting 8-OHdG in a human urine sample. We observed no noticeable difference in the 
standard curves obtained with artificial urine (AU) (Figure 45), suggesting that the other 
components of urine do not interfere with the detection of 8-OHdG with Gel-BSA-OHG 
substrate and anti-8OHdG antibody. 
 
 
  
Figure 45 Interference studies with artificial urine in Competitive ELISA 
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2.3.4 Lateral Flow Immunoassay: Testing of 8-OHdG in paper assay 
The paper strip assay was assembled on a nitrocellulose membrane. The conjugate pad was 
coated with Au-antiOHdG conjugate.  The test pad was coated with Gel-BSA-OHG substrate 
and the control pad was coated with anti-mouse IgG (secondary antibody). The paper strip which 
was 3 mm wide and 6 cm long was used as a dip sensor. The paper strip was dipped in OHDG 
solution of varying concentrations and the colorimetric intensity of the test line was captured 
using a smartphone. The images obtained were analyzed using ImageJ software. Different 
smartphones and smart devices were used to capture the images like Samsung S6, Lumia and 
Cool pad. The intensity of the test line decreased with increasing concentration of the 8-OHdG 
concentrations. The intensity of the test lines was normalized with the background intensity of 
the nitrocellulose membrane for all the images. The color of the test line started to appear within 
1 hour of the initiation of the experiment.  A test was conducted to confirm that the strip does not 
react with other components of the human urine. The strips were dipped in artificial urine added 
with varying concentration of 8-OHdG and the intensity of the test line was captured through a 
smartphone camera and the images were analyzed through ImageJ software. The strips did not 
seem to interfere with any of the other components of the artificial urine and exhibited a 
decreasing intensity with increasing 8-OHdG concentration (Figure 46).   
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a)    b)  
 
2.3.5 Analysis of Urine samples using Competitive ELISA and LFIA 
Urine samples were collected from infants admitted in NICU with the parents’ consent using a 
cotton ball. The inclusion criteria was that the babies should be born before 32 weeks or their 
weight is less than 1500g. Samples were collected at different time points and were stored in -20o 
C till they were analyzed. A total of 209 samples from 32 patients were analyzed. The 8-OHdG 
level in the urine samples was analyzed using 96 well Competitive ELISA as well as lateral flow 
based paper strip assay. Standard curves with known 8-OHdG concentrations were used as a 
controls .   The results were correlated with the ROP status of the patients as examined by the 
ophthalmologist. The 8-OHdG levels in the two different methods were also correlated. A 
student t-test was performed to compare the differences between the values of OHDG of patients 
with and without ROP (p<0.01).  The ROP status was divided in three groups: Stage 0, Stage 1 
and Stage 3.  The average 8-OHdG values of the patients as recorded from both ELISA and 
LFIA in all the three categories were calculated. The average values of the 8-OHdG of patients 
Figure 46 a) Colorimetric intensities of control line with increasing conc. Of 8-OHdG b) Standard curve of the intensities 
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with Stage 1 and Stage 3 ROP was significantly higher than those with Stage 0 or No ROP. 
(Figure 47).  
a)   b)   
The amount of 8-OHdG in the urine samples was analyzed using competitive ELISA method as 
well as LFIA method. The 8-OHdG values were plotted for patients with ROP and patients with 
no ROP.  The values obtained from competitive ELISA method suggested that 8-OHdG values 
were higher in patients with ROP as compared to patients with no ROP. However, there were a 
five outliers observed for stage 0 ROP values .The distribution plot of 8-OHdG values showed 
that the patients with Stage1 or Stage 3 ROP had 8-OHdG values ranging from 35 ng/ml to 100 
ng/, while the value was less than 35 ng/ml for patients with Stage 0 ROP ml (Figure 48 a).  
Similar results were observed for 8-OHdG values obtained with LFIA (Figure 48 b). However, 
the number of outliers for Stage0 ROP was 2 for LFIA method. 
 
                 
Figure 47 a) Colorimetric Intensity of test line for urine samples with Stage 0, Stage 1 and Stage 3 ROP respectively 
                b) Average 8-OHdG values for patients with Stage 0, Stage 1 and Stage 3 ROP respectively 
74 
 
a)     b) 
 
8-OHdG levels of all the time dependent samples for each of the patients were plotted (Figure 
49). Some patients developed ROP over the course of time and the values of the 8-OHdG for the 
time points correlated with the ROP status in most of the cases. It was observed that the patients 
who were diagnosed with ROP from the beginning presented a higher 8-OHdG levels than 
patients who developed ROP at a later stage.  There were 5 cases where the 8-OHdG levels of 
the patients were high even though they were not diagnosed with ROP. Since, 8-OHdG is an 
oxidative stress marker, there might have been some other complications that might have caused 
the spike in the 8-OHdG levels. However, the average 8-OHdG levels of patients who had 
consistent or had developed ROP was higher than that of the patients without ROP. (Figure 50)  
 
 
Figure 48 a) Distribution of 8-OHdG values for patients with and without ROP as analyzed by traditional ELISA 
                b)  Distribution of 8-OHdG values for patients with and without ROP as analyzed by LFIA paper assay 
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Figure 49 8-OHdG values of each sample of the patients in chronological order 
Figure 50 Average 8-OHdG values of each of the patients 
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2.4 Conclusion 
From the ELISA results it is concluded, that levels of 8-OHdG can be correlated with onset of 
ROP.  We did not notice a significant difference in the average values of 8-OHdG for patients 
with Stage 1 and Stage 3 ROP. However, there was a significant difference between the average 
8-OHdG values of patients with Stage 0 (No) and Stage1 or Stage 3 ROP. This demonstrates that 
8-OHdG is could serve as a valid marker to determine the onset of ROP and not necessary a tool 
to indicate the stage of ROP. The distribution values and average plots of the 8-OHdG values for 
both competitive assay and ELISA indicate that the patients with ROP have an average 8-OHdG 
value higher than 25-30ng/ml. Thus, for the purposes of a screening, the cutoff value for the 
patients would be 25ng/ml 8-OHdG. The patients who are at risk of developing ROP, i.e. 
patients who were born before 32 weeks or who are born with a weight less than 1500gm would 
be screened for ROP. Urine samples from these patients would collected at 24 hours after their 
birth and then at 72 hours and then once every week till they are discharged. If the 8-OHdG 
values of the patient remains under 30ng/ml, the patient is not at risk of developing ROP. 
However, if the value of 8-OHdG increases to 50ng/ml or above, the patient is at risk of 
developing ROP and the child would be checked for ROP by physical examination by an 
ophthalmologist. Since 8-OHdG is an oxidative stress marker, the levels of 8-OHdG can be 
affected by some other exacerbations like brochopulmonary dysplasia (BPD), hyperglycemia, 
number of days in incubator and number of days in the NICU.  The status of BPD, 
hyperglycemia and number days in incubator and NICU data was collected from the clinics and 
the regression analysis was conducted to determine the influence of each of these factors in the 
values of 8-OHdG. It was observed that the status of BPD, hyperglycemia and number of days in 
the incubator did not have any effect on the outcome of the values of 8-OHdG. However, it was 
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noticed that there was a correlation between 8-OHdG values and the number of weeks spent at 
the NICU. The 8-OHdG values were high for patients who had been in NICU for more than 8 
weeks. Hence, for screening purposes, the screening should be limited to 8 weeks in the NICU. If 
the patient is in the NICU for a longer time, the 8-OHdG levels would be high and might not 
corroborate with ROP status of the patient. Future studies with a larger sample will be required 
to establish 8-OHdG as a robust biomarker for the screening of ROP.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
78 
 
References 
 
Afrasiabi, Z., Shukla, R., Chanda, N., Bhaskaran, S., Upendran, A., Zambre, A., . . . Kannan, R. 
(2010). Nanoscale Sensor Design via <I>In Situ</I> Labeling of Gold Nanoparticles onto 
Protein Scaffolds. Journal of Nanoscience and Nanotechnology, 10(2), 719-725. 
doi:10.1166/jnn.2010.1906 
Asano, M. K., & Dray, P. B. (2014). Retinopathy of prematurity. Dis Mon, 60(6), 282-291. 
doi:10.1016/j.disamonth.2014.03.009 
Ates, O., Alp, H. H., Caner, I., Yildirim, A., Tastekin, A., Kocer, I., & Baykal, O. (2009). 
Oxidative DNA damage in retinopathy of prematurity. Eur J Ophthalmol, 19(1), 80-85.  
Chen, J., & Smith, L. E. H. (2007). Retinopathy of prematurity. Angiogenesis, 10(2), 133-140. 
doi:10.1007/s10456-007-9066-0 
Chen, J., Stahl, A., Hellstrom, A., & Smith, L. E. (2011). Current update on retinopathy of 
prematurity: screening and treatment. Current Opinion in Pediatrics, 23(2), 173-178. 
doi:10.1097/MOP.0b013e3283423f35 
Hinokio, Y., Suzuki, S., Hirai, M., Suzuki, C., Suzuki, M., & Toyota, T. (2002). Urinary 
excretion of 8-oxo-7, 8-dihydro-2'-deoxyguanosine as a predictor of the development of 
diabetic nephropathy. Diabetologia, 45(6), 877-882. doi:10.1007/s00125-002-0831-8 
Naidu, B. V. K., & Paulson, A. T. (2011). A new method for the preparation of gelatin 
nanoparticles: Encapsulation and drug release characteristics. Journal of Applied Polymer 
Science, 121(6), 3495-3500. doi:10.1002/app.34171 
Wu, L., Pu, W., Liu, Y., Zhao, H., & Shu, W. (2015). Visual detection of 8-OHdG based on the 
aggregation of gold nanoparticles capped with the anti-8-OHdG antibody. Analytical 
Methods, 7(19), 8360-8365. doi:10.1039/c5ay01774b 
79 
 
Wu, L. L., Chiou, C. C., Chang, P. Y., & Wu, J. T. (2004). Urinary 8-OHdG: a marker of 
oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin 
Chim Acta, 339(1-2), 1-9.  
Zhu, X., Hondroulis, E., Liu, W., & Li, C.-z. (2013). Biosensing Approaches for Rapid 
Genotoxicity and Cytotoxicity Assays upon Nanomaterial Exposure. Small, 9(9-10), 
1821-1830. doi:10.1002/smll.201201593 
Zhu, X., Shah, P., Stoff, S., Liu, H., & Li, C. Z. (2014). A paper electrode integrated lateral flow 
immunosensor for quantitative analysis of oxidative stress induced DNA damage. 
Analyst, 139(11), 2850-2857. doi:10.1039/c4an00313f 
 
.   
 
 
 
 
 
 
 
 
80 
 
CHAPTER 3 
NANOPARTICLE BASED ASSAY FOR SCREENING DIABETIC 
RETINOPATHY  
3.1 Introduction 
3.1.1 Diabetic Retinopathy: Background 
Diabetes Mellitus (DM) is one of the most endemic diseases around the globe. It is estimated that 
the number of DM cases will increase from 171 million in 2006 to 366 million by 2030 (WHO, 
Case reports on Diabetes, 2012).    In spite of the advances in medicine, the rapid escalation of the 
DM cases over the past few decades can be attributed to sedentary lifestyle and increased obesity 
amongst adults and children. Diabetes Mellitus (DM) is a metabolic disease which impairs the 
body’s ability to breakdown glucose, resulting in accumulation of glucose in the blood 
stream(Madsen-Bouterse & Kowluru, 2008).   
The accumulation of glucose in the system results from either the reduction in insulin production 
(Type 1 diabetes) or the body’s inability to breakdown insulin (Type II diabetes). The excess 
glucose in the circulatory system gradually starts to affect different vasculatures of the body, 
leading to micro and macro vascular complications (R. A. Kowluru, Kowluru, Mishra, & Kumar, 
2015). Macro vascular complications include cardiovascular disease while micro vascular 
complications include, nephropathy, neuropathy and Diabetic Retinopathy (Eshaq, Aldalati, 
Alexander, & Harris, 2017).  
Diabetic Retinopathy (DR) is a slow progressing disease which affects the retina leading to 
impaired vision or complete vision loss.  DR is the primary cause of acquired blindness among 
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adults with Diabetes Mellitus (DM).  According to the National Eye Institute the incidence of DR 
is projected to double from 7.7 million in 2010 to 14.6 million in 2050 in the USA. The number 
of DR and vision threatening DR cases is estimated to rise to 191 million and 56.3 million 
respectively by 2030.  DR is a significant health problem causing huge economic burden to 
developing as well as developed counties. The main challenge faced by the medical community is 
that DR is asymptomatic till it has progressed to an advanced stage. Hence, early screening of DR 
for patients with diabetes will allow prevention of blindness or severe retinal damage.   
3.1.2 Diagnosis of DR and Challenges 
The current gold standards for diagnosing DR are Fundus Photography (with a Fundus camera 
based on indirect Ophthalmoscope) and Fluorescein Angiography. Diabetic Retinopathy is 
asymptomatic for several years. The first visible symptoms of DR are the appearance of micro 
aneurysms in the retina (small area of blood protruding from the vein) and internal hemorrhages 
(ruptured micro aneurysms) which can be detected by Fundus photography (Cunha-Vaz & World, 
2011). Other symptoms include capillary occlusion and hard exudates (extracellular accumulation 
of lipoproteins), which are detectable by Fluorescein angiography.  
DR can be classified as Non-Proliferative and Proliferative DR. Non-Proliferative DR (NPDR), 
which is a less severe manifestation of DR, can be further be classified as mild, moderate and 
severe (Cunha-Vaz, 2011). Mild NPDR is characterized by sparsely populated micro aneurysms, 
while  Moderate NPDR is characterized by an increase in the number of hemorrhages, hard 
exudates and retinal arterioles(Pickup & Williams, 1994). Severe retinopathy follows as the 
number of aneurysms increase further (Figure 51).  Proliferative DR involves the formation of new 
blood vessels arising from the disc or retinal periphery which might cause retinal detachment and 
blindness (Pickup & Williams, 1994).  
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The presentation of these symptoms imply that the retinal cells were subjected to oxidative damage 
due to hyperglycemia over several years. The damage is often irreversible and leads to increased 
health care cost for the patients. Regular screening and checkup might help manage the symptoms 
and lead to better treatment options. However, patients from lower economic backgrounds might 
find it burdensome to go through regular DR screening checkups and hence might miss the initial 
stages of DR leading to an increased risk of blindness or severe retinal damage. Currently, there is 
no portable and easy diagnostic procedure that can detect the onset of DR at an earlier stage.  
  
                                   
 
 
3.1.3 Clinical need 
 It is crucial to develop an in-home and cost effective screening technique that would indicate the 
early onset of the DR. This will help control the progression of the disease and also reduce the 
medication cost.   The ideal diagnostic technique would allow the detection of DR at an earlier 
stage (when the retinal blood-vessel damage starts to occur), using a suitable biomarker.  
 
Normal Eye      NPDR (Initial stage)     PDR (Late stage) 
Figure 51 Schematic of the Eye in different stages of Diabetic Retinopathy 
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3.1.4 Pathogenesis of Diabetic Retinopathy (DR) 
 To identify a suitable biomarker for the screening of DR, it is important to understand the 
pathogenesis and the molecular pathways of DR in the retina.   The retina is a complex structure 
of  several types of cells which include the vascular (pericytes and endothelial cells), neurons 
(photoreceptors, second-order neurons and ganglion cells), macroglia (Muller cells and 
astrocytes), and the microglia (Forrester, 2002) (Figure 52 a, 52 b). Excess glucose in the 
circulatory system disrupts the metabolism pathways in the retina and the capillary cells (Lechner, 
O'Leary, & Stitt, 2017). Under hyperglycemic conditions, the neural cells and the Muller cells 
undergo increased apoptosis which leads to neuronal cell death (R. A. Kowluru et al., 2015). The 
endothelial and pericyte cell loss due to diabetes is another major contributing factor in the 
development of DR. The onset of DR  is also characterized by increased permeability of the blood 
retinal barrier (Eshaq et al, 2017). In addition, it has been reported that DR leads the mitochondrial 
dysfunction in the retina and its capillary cells along with change in mitochondria morphology and 
membrane potential. This leads to elevated superoxide radicals and compromised oxygen 
consumption (Madsen-Bouterse & Kowluru, 2008).  Understanding the biochemical pathways 
responsible for these changes is important to identify the biomarker which can be directly 
correlated with the onset of DR.  
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Several metabolic pathways have been implicated in the development of DR. The most common 
pathways studied for diabetes are the i)polyol pathway, ii) formation of advanced glycation end 
products, iii) activation of protein kinase C (PKC) and the iv) Hexosamine pathway and oxidative 
stress.  Out of all the mechanisms, the oxidative stress has been reported to be the most important 
reason for the damage of the retinal cells (Kowluru et al, 2015). The pathways are described in 
detail below: 
i) The Polyol Pathway: In normal conditions, only a small amount of glucose is processed 
through the polyol pathway as aldose reductase has low affinity for glucose.  When there is 
excess of glucose in the circulatory system, aldose reductase converts the unused glucose to 
sorbitol by using NADPH as a cofactor. The reduced levels of NADPH in turn leads to a 
reduction in glutathione levels and increased oxidative stress, an underlying factor in diabetic 
retinopathy. Sorbitol is further oxidized to fructose by sorbitol dehydrogenase during which 
NAD+ is reduced to NADH.   Sorbitol is less permeable through the cell membrane and hence it 
accumulates in the cells causing osmotic damage (Mathebula, 2015).  
Normal Eye Structure of Retina 
Figure 52 a) Schematic of Normal Eye b) Schematic of the different cells inside of Retina 
85 
 
ii)Advanced Glycation End products: The polyol pathway produces fructose which is 
phosphorylated to fructose -3-phosphate and 3-deoxyglucosone both of which participate in the 
formation of advanced glycation end products (AGEs). AGEs are a product of non-enzymatic 
reduction of sugars with amino acids and proteins, and Diacylglycerol (DAG).   The accretion of 
AGEs under hyperglycemic conditions disrupts the microvascular homeostasis.  AGEs interact 
with a receptor called RAGE which is a primary contributor in inflammation and microvascular 
dysfunction in diabetic retinopathy(Safi, Qvist, Kumar, Batumalaie, & Ismail, 2014). 
iii)Activation of Protein Kinase C: Increased sorbitol dehydrogenase activity in the cells effects 
an increased NADH/NAD+ ratio leading to an increase in DAGs by inhibiting triose phosphate, 
which in turn activates Protein Kinase C (PKC) and increases cytokine production in cells. The 
activated PKC contributes to the basement membrane thickening, vascular occlusion, increased 
vascular permeability and activation of angiogenesis. Activation of PKC also results in vascular 
permeability and disruptions in the retinal blood flow and development of neovascularization 
(Eshaq et al, 2017) (Mathebula, 2015).  
iv) Activation of Hexosamine Pathway: The Hexosamine pathway is activated under 
hyperglycemic conditions wherein some of the glucose in converted to glucose-6-phosphate and 
fructose -6-phosphate. The fructose-6-phosohate is converted to glucosamine-6-phosphate which 
in turn are metabolized to uridine diphosphate-N-acetyl glucosamine (UDPGlcNAc) and UDP-
N-acetylgalactosamine. They act as substrates for glycosylation which leads to gene and protein 
function alterations and apoptosis (Eshaq et al, 2017) (Mathebula, 2015). 
The end product of the polyol pathway and as a result all the other pathways is the production of 
reactive oxygen species (ROS) which produce oxidative stress in the cells (Figure 53).An 
imbalance in the ROS production leads to macro molecular protein and DNA damage in the 
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cells. It also affects the mitochondria and the electron transport chain which initiates a cascade of 
reactions leading to mitochondrial dysfunction and leads to further production of ROS and 
superoxides (Renu A. Kowluru & Mishra, 2015). The mitochondrion plays an important role in 
the production of ROS and in the pathogenesis of DR. 
 
 
3.1.5 Mitochondria and production of ROS  
The mitochondrial electron transport chain includes four protein complexes called complex I, II, 
III and IV. In normal circumstances, the glucose is metabolized through the Tricarboxylic acid 
(TCA) cycle, which produces electron donors, primary of which is called NADH which gives 
electron to complex I (Brownlee, 2005). The energy of the electrons across the membrane is used 
to pump protons to complexes I, II, III and IV. The transport of protons creates a voltage 
difference across the membrane which drives the synthesis of ATP by ATP synthase.  Under 
hyperglycemic conditions, the voltage gradient across the membrane is increased till a threshold 
point is reached. Beyond this point, the electron is unable to be transferred to complex III 
causing the electrons to accumulate at coenzyme Q, which results in the formation of superoxide 
Figure 53 Molecular mechanisms inside the cell and mitochondrion under hyperglycemic and DR conditions 
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(Brownlee, 2005). In DR, this impaired complex III activity is noticed in the retinal and capillary 
cells which leads to increased ROS in the cell. The increased cytosolic ROS in diabetes activate 
the MMPs in the retina. The activated MMPs damage the mitochondrial membrane and disrupt 
the functioning of the Complex III protein and subsequently the antioxidant scavenging 
machinery is compromised. This leads to accumulation of free radicals in the mitochondria and 
leads to vicious cycle of mitochondrial damage and production of superoxide or free radicals. 
The increased mitochondrial ROS disrupts the nuclear DNA by breaking the double strands. The 
DNA present in the mitochondria are circular and lack histones. These mitochondrial DNA in the 
retina are prone to oxidative damage. The guanine bases in the DNA are modified to form 8-
OHdG (8-hydroxy 2-deoxy guanosine). Hence, there is an increase in 8-OHdG production in the 
mitochondria in the retinal cells of the patients with DR.  
3.1.6 8-OHdG as a biomarker  
Mitochondrial DNA from tissue and blood lymphocyte are prone to oxidative damage. The 
guanine in the DNA undergoes oxidation, wherein a hydroxyl group is added at the 8th position 
of the guanine molecule (Figure 54). 8-OHdG is the most prominent form of free radical induced 
DNA lesion. After the damage occurs, the cells have the capability to recognize and remove the 
oxidized lesion by base excision pair mechanism. The oxidized guanine is cleaved by enzymes 
such as endonuclease and glycosylase, removed from the cell into the blood which is then further 
excreted out through the urine. Hence, the amount of 8-OHdG in the system is indicative of the 
extent of DNA damage taking place in the body. The oxidized nucleosides like 8-OHdG are not 
further metabolized in the system and are excreted through the urinary system as they are easily 
soluble in water(L. L. Wu et al., 2004). Thus, the amount of urinary 8-OHdG reflects the level of 
oxidative damage taking place in the body.  Few research groups have reported that urinary 8-
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OHdG/creatinine levels are higher in patients with Diabetic Nephropathy as compared to patients 
with no Diabetic Nephropathy or retinopathy (Hinokio et al., 2002). The studies were conducted 
in a cohort of 396 patients in Japan.  
 
 
3.1.7 Detection of 8-OHdG 
The most commonly used analytical techniques for the detection for 8-OHdG are high-
performance liquid chromatography-electrochemical detection (HPLC-ED), HPLC tandem mass 
spectrometry, gas chromatography-mass spectrophotometry (GC-MS), Capillary Electrophoresis 
with electrochemical detection (CE-ECD)(X. Zhu et al., 2014). These techniques have good 
sensitivity and accuracy, however these are lab based techniques requiring expensive 
instrumentation and trained personnel.  Enzyme Linked Immunoassay (ELISA) is also used for 
the colorimetric detection of 8-OHdG. 8-OHdG is a small molecule, hence the major challenge is 
to immobilize it for the purposes of capture and detection (L. L. Wu et al., 2004). The most 
common method for detection of 8-OHdG is by conjugating it with a heavy protein like BSA 
(Bovine Serum Albumin) and conducting a competitive ELISA for the detection and analysis. 
Albeit being less complex than HPLC techniques, it is still is a lab based and labor intensive 
technique. Hence, it is not suitable for bed side or in-house detection of 8-OHdG. For these 
Figure 54 Oxidization of guanine base of mitochondrial DNA to form 8-OHdG 
89 
 
purposes, there is a need for the development of a point-of-care testing device which is portable 
and has faster readout times. A Lateral Flow Immunoassay (LFIA) is a paper based assay 
techniques which is based on the principle of sample movement through capillary flow on a 
nitrocellulose membrane (X. Zhu et al., 2014). It is also a colorimetric technique, where the 
amount of the analyte is visualized based on the color intensity of the sensor. The sensor has high 
sensitivity and can be comparable with other established lab procedures.  
3.1.8 Hypothesis and Solution 
  Hinokio et al found a significant progression of diabetic nephropathy and diabetic retinopathy 
with increased levels of 8-OHdG in urine. A few studies in Japan and South Korea have 
demonstrated that amount of 8-OHdG can have a direct correlation with the onset of DR(Ref). 
From these initial studies, we extrapolated and hypothesized that the amount of urinary 8-OHdG 
and the 8-OHdG/Creatinine ratio will be higher in patients with DR than in patients with no DR 
in a cohort of Caucasian population. To this effect, we conducted a study with a two-pronged 
approach. First, we developed different substrates for the accurate and fast detection of 8-OHdG. 
Secondly, we conducted an exploratory study to examine whether urinary 8-OHdG levels can be 
correlated with the status of DR in a cohort of Caucasian population (n=80). We developed a 
library of BSA-OHG substrates by conjugating BSA-OHG to different nano and micro particles. 
We then developed a paper (nitrocellulose) based colorimetric dip sensor, a Lateral Flow 
Immunoassay (LFIA) to develop a fast and portable platform for the detection of urinary 8-
OHdG. The different colorimetric substrates used was gold nanoparticles and gold nanoclusters 
respectively.  
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3.1.9 Competitive ELISA 
Enzyme Linked Immunoassay (ELISA) is a gold standard for detecting molecules in biological 
assays (Santella, 1999). It is a highly sensitive and accurate colorimetric method for analysis of 
biological molecules and has been widely utilized for analyzing proteins, antigens and 
oligonucleotides and small molecules (L. L. Wu et al., 2004). Some studies have reported the 
detection of urinary 8-OHdG by competitive ELISA techniques (Hinokio et al., 2002) (Chiou et 
al., 2003). 8-OHdG is a small molecule, hence the major challenge is to immobilize it for the 
purposes of capture and detection(L. L. Wu et al., 2004). 8-OHdG is conjugated with a protein 
molecule like BSA for improved adherence to the substrate (Wu et al). Competitive ELISA is 
based on the principle of competitive binding of the antigen to the antibodies (Figure 55). The 
signal intensity is inversely proportional to the concentration of antigen in the sample.  Despite 
being sensitive and accurate and less complex than HPLC and Mass Spec, ELISA is still lab 
based technique which both labor intensive and time consuming. In order to develop a simple in-
home sensor,  it is important to develop a more portable and easy to use Point-of-Care device. 
 
Figure 55 Schematic of the working principle of Competitive ELISA on a 96 well plate 
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3.1.10 Lateral Flow Immunoassay (LFIA) 
An ideal point of care device should enable fast and accurate detection of 8-OHdG without the 
need of any complex equipment. A lateral flow immunoassay is a chromatographic assay which 
works on the principle of capillary flow on a nitrocellulose membrane (Zhu et al, 2014). The 
qualitative or quantitative status of the analyte is visualized through a colorimetric substrate. The 
signal readout is usually done by capturing images in a smartphone and analyzing through image 
analysis software. A paper strip consists of a sample pad, conjugate pad, test line, control line 
and the absorbent pad. The signal intensity is inversely proportional to the amount of analyte 
present in the sample (Figure 56). 
 
3.1.11 Metallic Nanoparticles and Nanoclusters  
Gold nanoparticles exhibit unique optical and surface properties and are widely utilized in 
biological applications like determination of tumor biomarkers, toxins etc. (Wu et al, 2015). The 
advantages of gold nanoparticles are that they are highly biocompatible, easily modified for 
surface functionalization.  (Wu et al, 2015). Another important property of gold nanoparticles is 
Figure 56 Schematic of the working principle of Lateral Flow Immunoassay based Paper sensor 
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the induction of Localized surface Plasmon resonance (LSPR) on incidence of light. The 
nanoparticles absorb and scatter light with greater intensity than their bulk material counterparts 
(Anker et al, 2008). This property enables the gold nanoparticles to be used as colorimetric labels 
for immunoassays and other biological applications (Anker et al, 2015) (Figure 57).  In this 
project, gold nanoparticles were used as colorimetric substrates for detection of 8-OHdG in paper 
strip based Lateral Flow Immunoassay. The gold nanoparticles were functionalized with anti-8-
OHdG antibody using electrostatic binding  
 
 
Fluorescence is another common technique used for the detection of the several analytes (Shang, 
Dong, & Nienhaus, 2011). Generally, fluorophores are conjugated with antibodies or other 
nanoparticles to impart the fluorescent properties of the substrate.  There have been some reports 
suggesting that Gold ions reduced and sequestered in a protein solution form gold nanoclusters 
of 20 nm size which have altered optical properties (Xie, Zheng, & Ying, 2009) ( Figure 58 a). 
These nanoclusters exhibit a bright pink color when they are exposed to UV light (Figure 58 c). 
The fluorescent properties of the gold nanoclusters can be used as an ELISA substrate as well as 
Figure 57 Schematic of conjugation of anti-8-OHdG antibody to Gold nanoparticle 
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for the lateral flow paper sensor. We have utilized the fluorescent nanoclusters for competitive 
ELISA assays.                                
 
a)          b)         c)  
 
3.1.12 BSA-OHG substrates for 8-OHdG detection 
8-OHdG is a small molecule and its direct immobilization on any surface is challenging. The 8-
OHdG must be conjugated with a carrier protein like BSA (Bovine serum albumin) (Ref). We 
have conjugated BSA with 8-OHdG by a periodate oxidation method. The diol groups of the 
ribose moiety are oxidized to dialdehyde which is then conjugated with the amino groups of the 
amino acid by carbodiimide bond (Figure 59) (Ref).  From initial ELISA experiments it was 
observed that BSA-OHG was amenable to being washed away after several washing steps. We 
explored the immobilization of BSA-OHG by conjugating with other protein nanoparticles and 
beads.  
 A library of BSA-OHG conjugates were prepared by conjugating it with gelatin nanoparticles, 
Latex beads and magnetic nanoparticles  
Figure 58 a) Schematic of Gold-BSA (Au-BSA) nanoclusters b) Dark red color of Au-BSA under normal light c) Bright pink 
color of Au-BSA nanoparticle under UV (Ultraviolet Ray) 
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Gelatin is a versatile protein which is obtained from denaturation of collagen (Naidu & Paulson, 
2011). Gelatin nanoparticles formed by two step de-solvation method with acetone precipitation 
and crosslinked with glutaraldehyde are very robust nanoparticles that are used for several 
applications (Coester, Langer, van Briesen, & Kreuter, 2000). The gelatin nanoparticles can be 
covalently conjugated with antibodies and used as substrates for ELISA and LFIA.  (Figure 60) 
ELISA studies showed that these nanoparticles are more adherent to the surface as compared to 
the other conjugates. We chose the Gel-BSA-OHG as the robust substrate for all the consecutive 
ELISA and LFIA experiments for optimization and clinical studies.  
 
 
We conducted optimization studies with the Gel-BS-OHG conjugates and AuNp nanoparticles 
for ELISA and LFIA assays. We also analyzed urine samples from 80 patients with and without 
8-OHG BSA-OHG 
Figure 59 Schematic of synthesis of BSA-OHG conjugate using periiodate reduction method 
Figure 60 Schematic of synthesis Gelatin-BSA-OHG conjugate using EDC/NHS 
conjugation
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DR. We analyzed the samples using Competitive ELISA and Lateral Flow Immunoassay and 
found that both the assay results correlated well with the Fundus Results.  
 
3.2 Materials and Methods 
3.2.1 Materials 
HAuCl4 (Hydrogen Tetraaurochlorate) was purchased from Acros Organics. Bovine Serum 
Albumin (BSA), Sodium Periodate, 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide(EDC) and 
Bicinchonic assay kit were purchased from Sigma Aldrich. Gelatin, Sodium citrate trihydrate, 
Hydroxy sulfo succinimide (Sulfo-NHS) were purchased from Thermo Fisher Scientific. OHG 
and 8-OHdG were purchased from Cayman Chemicals. Anti-8-OHdG [15A3] antibody was 
purchased from AbCam. Anti-Mouse IgG-HRP was purchased from Jackson Laboratories. 
Polyethylene Glycol-NHS (PEG-NHS) and succinimidyl PEG-NHS were purchased from Nanocs. 
TMB substrate was purchased from BioRad. The Nitocellulose membrane, the sample pad and the 
conjugate pad were purchased from Millipore. Artificial Urine was purchased from QuikFix.  
3.2.2 Instruments 
Core nanoparticle size measurements were performed using Joel TEM. Hydrodynamic size and 
zeta potential was measured using a Malvern Zetasaizer Nano-ZS. Centrifugation was 
performed on a 5424 Eppendorf and refrigerated RC 6+ Sorvall centrifuge. pH was measured 
using a Seven Compact Mettler Toledo pH meter equipped with an InLab Micro electrode. 
Fluorescence imaging, fluorescence assays and UV-vis absorption assays were performed on 
a Cytation 5 Cell imaging multi-mode reader. Gel electrophoresis was performed on a Biorad 
Mini-Protean Tetra system and blots were transferred using a Genscript e-blot transfer system. 
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Western blot imaging and acquisition was performed using Image Lab ver 5.2.1 software on a 
ChemiDoc XRS system from Biorad. Band densitometry analysis was performed on Image 
Studio ver 5.2. Solvent extraction was performed on a Büchi Rotovapor R-124 attached to a 
water bath and watercoo led distillation column. SQUID measurements were performed on a 
Quantum Design MPMS 3 Magnetometer. The antibodies and substrate were coated on the 
paper strip using a Camag Linomat 5 automated dispenser.  
 
3.2.3 Synthesis of Fluorescent Gold nanoparticles 
Fluorescent Gold nanoparticles were synthesized based on a previously published protocol with a 
few modifications(Xie et al., 2009). BSA (250mg) was dissolved in 5ml DI water followed by 
addition of 5ml HAuCl4 solution (10mM) and heated to 37oC by stirring continuously. When the 
solution reached 37oC, the pH was adjusted to 12.0 by adding 1M NaOH and stirred overnight at 
37oC to get a dark red color.  The Au-BSA nanoclusters thus formed are fluorescent and can be 
checked for fluorescence under portable UV light. The Au-BSA nanoparticles were functionalized 
with PEG-NHS (MW 2000) to block the amine groups in the BSA to prevent crosslinking. Briefly, 
2ml of washed Au-BSA nanoparticles were taken in a vial.  The pH of the solution was adjusted 
to 7.5 with MES buffer. 50mg of PEG-NHS was added to the pH adjusted solution and stirred 
overnight at room temperature. The PEGylated Au-BSA nanoclusters were purified by passing 
them through 100kDa centrifugal filters three times.  The PEGylated Au-BSA nanoclusters were 
conjugated with Anti-8-OHdG antibody using EDC-NHS conjugation.  2mg of EDC and 3 mg 
NHS in 40ul MES buffer was added to 200l PEGylated Au-BSA nanoclusters (pH 4.5) followed 
by activation at RT for 4 hours. The activated nanoparticles were passed through 100kDA filter at 
6000g to remove excess EDC and NHS. 10l of 1mg/ml Anti-8-OHdG antibody was added to the 
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particles and the pH of the solution was increased to 7 by adding 0.1M followed by overnight 
mixing at RT in a thermomixer. The antibody conjugated Au-BSA nanoclusters were passed 
through 100kDa filter at 6000g to remove any excess antibody. 
3.2.4 Synthesis of BSA-OHG Conjugate 
BSA-OHG conjugate was synthesized based on a previous publication with some modifications 
(Xuena Zhu et al., 2013).  BSA solution was prepared dissolving 12.5mg BSA in 1 ml of 50mg/ml 
K2Co3. 8-OHG (0.5 mg) was dissolved in 100 µl of periodate and mixed in dark conditions for 1 
hour in a thermomixer at RT. 200l of the prepared BSA solution was added to OHG solution and 
mixing was continued for 1 hour in dark followed by addition of 200ul of NaBH4 (24mg/ml). The 
solution mixed overnight at 4oC and passed through 10kDa filter. 
3.2.5 Synthesis of Gelatin nanoparticles 
Gelatin nanoparticles were synthesized using a two-step desolvation process (Coester et al, 2000) 
(Srikar et al., 2016). Gelatin type A (500 mg) was dissolved in 10 ml Deionized water (DIW) at 
50oC. 20 ml of acetone was added rapidly to initiate the first de-solvation process. The gelatin 
particles were precipitated and dissolved in 10ml DIW (pH 2.75) followed by second de-solvation 
by rapid addition of acetone (3ml/min) to form a milky solution. The nanoparticles were cross-
linked by adding 200µl 25% glutaraldehyde and stirring the solution overnight at 50oC. The gelatin 
nanoparticles were washed with DIW at 20,000g for 45 minutes for 5 times.  
3.2.6 Synthesis of Gel-BSA-OHG conjugate 
BSA-OHG was covalently conjugated with gelatin nanoparticles using EDS/NHS activation 
method (Ref). 1 ml Gelatin nanoparticles (6mg/ml) were centrifuged at 15,000g for 12 minutes. 
The supernatant was discarded and to the pellet 2.4 mg EDC in 3.6 mg of NHS were added in 
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40µl. The volume of the solution was made to 1ml and incubated in thermomixer at 24oC for 4 
hours. The activated nanoparticles were washed once to remove excess EDC and NHS. 36 µl of 
BSA-OHG in 1 ml 1X PBS was added to the nanoparticles and mixed overnight. The BSA-OHG 
conjugated nanoparticles were washed twice with 1X PBS. The final pellet was dissolved in 1X 
PBS. 
3.2.7 Competitive ELISA  
Competitive ELISA was used to test the specificity of the BSA-OHG conjugates. In this procedure 
the BSA-OHG conjugates were coated on a 96 well plate overnight at 4oC. The wells were washed 
and blocked with blocking buffer (2% milk). The primary antibody against 8-OHdG was added to 
the 8-OHdG solution (antigen) and incubated for 15 minutes prior to adding to the wells. The 
antibody-antigen solution was incubated with the BSA-OHG conjugate for 2 hours at 37oC. The 
wells were washed and incubated with the secondary antibody IgG-HRP conjugate for 30 minutes 
at 37oC followed by washing and addition of the TMB substrate. The wells were read at 450nm.  
3.2.8 Comparison of the BSA-OHG and Gel-BSA-OHG conjugates 
The 96 well plates were each coated with OHG, BSA-OHG and Gel-BSA-OHG conjugate 
overnight at 4oC. The wells were washed and blocked with blocking buffer (2% milk). The primary 
antibody against 8-OHdG was added to the OHdG solution (antigen) and incubated for 15 minutes 
prior to adding to the wells. The antibody-antigen solution was incubated with the BSA-OHG 
conjugate for 2 hours at 37oC. The wells were washed and incubated with the secondary antibody 
IgG-HRP conjugate for 30 minutes at 37oC followed by washing and addition of the TMB 
substrate. The wells were read at 450nm.  The experiment was repeated with Fluorescent gold 
nanocluster (fAuNC)-Antibody conjugates. The 96 well plates were each coated with OHG, BSA-
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OHG and Gel-BSA-OHG conjugate overnight at 4oC. The wells were washed and blocked with 
blocking buffer (2% milk).fAuNC-Antibody was added to the 8-OHdG solution (antigen) and 
incubated for 15 minutes prior to adding to the wells. The antibody-antigen solution was incubated 
with the BSA-OhG conjugate for 2 hours at 37oC. The wells were washed and incubated with the 
secondary antibody IgG-HRP conjugate for 30 minutes at 37oC followed by washing and addition 
of the TMB substrate. The wells were read at 450nm. 
3.2.9 Interference studies with Gel-BSA-OHG 
Interference studies were conducted to test whether the other components of the urine had any 
effect on the outcome of the 8-OHdG analysis assay. Commercially available artificial urine made 
by the company called Quikfix was used for the purposes. 100l Gel-BSA-OHG was coated on a 
96 well plate and incubated overnight at 4oC. ELISA was performed using artificial urine. OHdG 
was dissolved in artificial urine  instead of DIW and 50l of different concentrations of artificial 
urine solution mixed with OHdG were added along with 50l of anti-OHdG antibody solutions 
and the plates were read at 450nm using a Cytation 3. 
3.2.10 Monolayer vs Multilayer coating of Gel-BSA-OHG 
100µl of Gel-BSA-OHG was coated on the wells of a 96 well plate. In another well 60µl of gel-
BSA-OHG was coated. Due to the dimension of the well the 100l coating will form multiple 
layers on the well while the 60l coating will form a single or monolayer on the well. Competitive 
ELISA was performed to test the specificity of monolayer and multilayer coating. 
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3.2.11 Synthesis of Gold Nanoparticles (AuNPs) for Lateral Flow Immunoassay 
The AuNPs were synthesized by a modified citrate reduction method (Afrasiabi et al., 2010) 
Briefly, 50 ml of 0.01% HAuCl4 solution was heated to a boil followed by a rapid addition of 
trisodium citrate solution (1 mL, 1%) under vigorous stirring. After the color changed from yellow 
to red, the solution was continued to boil for another 10 min, then stirred without heating till the 
solution reached the room temperature.   
3.2.12 Synthesis of AuNP-Anti (8-OHdG) conjugate 
The AuNPs solution was concentrated 10X using a 70KD membrane filter. The pH of the AuNPs 
solution was adjusted to 8.5 ∼ 9.0 with K2CO3 (0.1 M).  The optimum concentration of antibody 
necessary for conjugating the AuNPs to stability is determined by a salt based aggregation test. 
The electrostatically stabilized AuNPs aggregate in the presence of salt till the surface is stabilized 
by enough protein. Briefly, 50µl of antibody of decreasing concentrations (1, 0.5, 0.25, 0.125, 
0.0625, 0.03125 mg/ml) were taken in separate tubes. They are incubated with 750 l of 10X 
AuNPs for 20 mins followed by the addition of 0.5 ml of 10% NaCl to all of them. We observed 
that the color of AuNP turned blackish blue and the LSPR peak underwent blue shift to all the 
concentrations below 0.5 mg/ml. Thus, 0.5mg/ml is the optimum concentration of the antibody. 
To ensure maximum loading of the antibody, the 10X AuNPs (900 l) were incubated with 50 μl 
of 1mg/ml purified anti-8-OHdG Ab at 750 rpm, RT for 1 hour. The conjugate was then incubated 
with BSA (10%) in sodium borate (20 mM) for a final concentration of 1% for another 20 min. 
Then the mixture was centrifuged for 15 min at 7000 rcf. The faint pink supernatant of unbound 
antibodies was discarded, and the pellet was resuspended in BSA/PBS (900 μl,1%) to further wash 
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away any unbound antibodies. Following the same centrifugation step, the supernatant was 
removed, and the soft sediment of conjugates was resuspended in conjugate pad buffer (900 μl). 
3.2.13 Lateral Flow Assay (Paper Strip Assay)  
The conjugate pad, sample pad and absorbent pad were assembled with 1-2 mm overlap on a 6 cm 
x 30.1 cm laminated cards with Hi-Flow Plus lateral flow membrane with a 0.19mm backing 
adhered to the surface of the card (HF180MC100 Millipore). Once assembled, Gel-BSA-8OHG 
(1mg/ml) and goat anti-mouse IgG (1mg/ml) were dispensed on the nitrocellulose membrane 
(2l/cm) using a Linomat 5 dispenser as test line and control line respectively. The assembly was 
then dried for 1 hour at 37 °C, cut into 4mm wide strips using a strip cutter and the strips were 
stored in the desiccator at RT. The 4mm wide strips were immersed in 80 ml of standards or urine 
samples in transparent plastic vials. The development of color was seen within 10 min. To 
maximize the color intensity and to maintain uniformity, the photographs of the strips were taken 
90 min after their dip in the standards/samples. The intensity of the color was quantified using 
ImageJ software. 
3.2.14 Analysis of 8-OHdG using LFIA 
80ul of 8-OHdG solutions of varying concentrations (0, 5, 10, 20, 40, 50 60, 70 ng/ml) were added 
to a quartz cuvette and the paper strip was dipped in the solutions. The color development on the 
test line was observed for the strips within 5 minutes and the test and control lines images were 
captured using a camera. The images were analyzed using ImageJ software and a standard curve 
was obtained by plotting the ratio of the intensity of test line/ nitrocellulose membrane against 
concentration (ng/ml) of 8-OHDG. 
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3.2.15 Interference studies with LFIA 
Interference studies were conducted to test whether the other components of the urine had any 
effect on the outcome of the 8-OHdG analysis assay. Commercially available Artificial Urine 
made by the company called Quikfix was used for the experiments. 8-OHdG was dissolved in 
artificial urine at various concentrations (0, 5,15,10,20 ng/ml) and 80l of the solution was added 
to quartz cuvette. The paper strip was dipped in the solution and the color development at the test 
and control lines was captured by a smartphone camera after 1 hour.  
3.2.16 Collection of clinical samples 
The IRB for the study was approved by the review board in University of Missouri, Columbia 
(IRB No 2004053). Urine samples were collected from patients above the age of 18, who visited 
the Mason Eye Institute at the University of Missouri, Columbia with their consent. The patients 
had no known history of cancer.  The urine samples were collected once from each patient and 
was stored at -20 C immediately till they were analyzed. Samples were collected from patients 
who were diagnosed with NPDR as well as from patients without DR. The urine samples were 
centrifuged at 3000g before analysis. Creatinine values were analyzed using a commercially 
available Creatinine assay kit by the MU Biorepository. 8-OHdG values were analyzed using 
Competitive ELISA as well as Lateral Flow Immunoassay.  
3.2.17 8-OHdG Analysis of clinical samples 
The urine samples were analyzed by both Competitive ELISA and LFIA procedures.  
For the competitive ELISA procedure, 60 Gel-BSA-OHG was coated on 96 well overnight at 4oC. 
The wells were washed and blocked with blocking buffer (2% milk). The primary antibody against 
8-OHdG was added to the 8-OHdG solution (antigen) and incubated for 15 minutes prior to adding 
103 
 
to the wells. The antibody-antigen solution was incubated with the BSA-OHG conjugate for 2 
hours at 37oC. The wells were washed and incubated with the secondary antibody IgG-HRP 
conjugate for 30 minutes at 37oC followed by washing and addition of the TMB substrate. The 
wells were read at 450nm.  
For LFIA, urine samples were centrifuged at 3000g. 80l of the samples were added to a quartz 
cuvette. The color development at the test and control line was captured using a smartphone after 
1 hour. The intensity of the test line of the urine samples was analyzed using ImageJ and the 8-
OHdG values were calculated based on the standard curve of known 8-OHdG values. 
3.3 Results and Discussion 
3.3.1 Synthesis and Characterization of BSA-OHG conjugate 
 The conjugation of BSA to OHG was ascertained by UV-Vis absorption of the BSA-OHG 
conjugate. The UV-vis absorption spectrum of the BSA-OHG was broader compared to that of 
the unconjugated BSA (Ref). The amount of OHG conjugated to BSA was estimated using UV-
Vis absorption. The conjugation efficiency of the OHG to BSA was estimated to be around 33%.  
3.3.2 Synthesis and Characterization of Gelatin nanoparticles 
Gelatin nanoparticles were synthesized by two step de-solvation process.  The hydrodynamic and 
core size of the nanoparticles was determined by Dynamic light scattering method (DLS) and 
Transmission Electron Microscopy (TEM) respectively. The TEM images confirmed formation 
of uniform nanoparticles with a size of 220nm (Figure 61). The zeta potential of the 
nanoparticles was 18 mV as recorded by the Zeta sizer. The results corroborated with the 
literature values (Srikar et al, 2015) 
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Gelatin nanoparticles were conjugated to BSA-OHG with EDC/NHS activation reaction (Ref). 
The conjugation of the BSA-OHG to Gelatin nanoparticles was confirmed using zeta potential 
measurement and hydrodynamic size. The conjugation efficiency was estimated to be around 
35% using Bradford and BCA assay and UV-vis absorbance technique. The hydrodynamic size 
and zeta potential of the nanoparticles are listed  in Table 3 
Construct Name Hydrodynamic size (d.nm) Zeta (mV) 
Gelatin  220 18 
Gelatin-BSA-OHG 250 10 
 
3.3.3 Synthesis and characterization of Gold Nanoparticle conjugates  
The gold nanoclusters were formed in situ at pH 12 and were stabilized by the BSA molecules. 
The fluorescent nanoclusters emitted a bright red fluorescence under UV light and exhibited 
excitation and emission peaks at 480nm and 640 nm respectively (Figure 62 a). TEM of the gold 
nanoclusters revealed that the core size was around 25 nm (Xie et al., 2009)(Figure 62 b).  The 
gold nanoclusters were functionalized with poly ethylene glycol polymer (PEG-NHS 2000) to 
Table 3: Hydrodynamic size and Zeta Potential of Gelatin and Gel-BSA-OHG nanoparticles  
Figure 61 TEM of Gelatin nanoparticles 
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introduce carboxyl groups to the nanocluster which would be utilized for antibody conjugation. 
The PEGylating of the nanocluster was confirmed by monitoring the changes in zeta potential 
and hydrodynamic size compared to starting material. The functionalized Gold NCs were 
conjugated with anti-OHDG antibody by activating the carboxyl groups with EDC/NHs reaction 
followed by conjugation with amine group in the antibody thereby forming a carbodiimide bond. 
The antibody conjugation was confirmed using UV-vis spectrum and zeta potential 
measurements. The zeta potential values decreased on addition conjugation of anti 8-OHdG 
antibody. 
a)      b)  
 
Gold nanoparticles were synthesized by reduction of gold ions using sodium citrate as a reducing 
as well as stabilizing agent. UV-vis absorbance was recorded to confirm the formation of gold 
nanoparticles which exhibit an absorbance peak at 520 nm (Afrasiabi et al., 2010) (Figure 63 a). 
Size and zeta potential analysis established a hydrodynamic size of 20 nm and zeta potential of -
19 mV and correlated well with reported values (Afrasiabi et al, 2010) . TEM Images of gold 
nanoparticles revealed the core size of 20 nm (Figure 63 b).  
Figure 62 a) Fluorescence of Gold Nanocluster b) TEM images of Gold nanocluster 
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a)  b)  
In order to conjugate anti-OHDG antibody to the Gold NPs, they were concentrated to 10X and 
the pH adjusted to 8. The antibodies were bound to the negatively charged gold nanoparticles via 
electrostatic binding. The conjugation was followed by blocking with BSA buffer to block the 
free surfaces of the gold antibody conjugate. The amount of antibody required for conjugation 
was determined by NaCl precipitation method (Figure 64).   
 
   
 
 
 
 
 
  3.3.4 Evaluation of BSA-OHG and Gel-BSA-OHG Substrate  
The binding affinity of BSA-OHG or Gel-BSA-OHG to antibody of OHG (anti-OHG) was 
investigated by ELISA using appropriate controls.  The binding affinity was monitored using a 
secondary antibody anti-mouse-IgG-HRP. We hypothesized that conjugation of OHG to BSA or 
Figure 64 Optimization of antibody concentration. No change in color when antibody is saturated. 
Figure 63 a) UV-Vis absorbance of Gold Nanoparticle b) TEM Image of Gold nanoparticle 
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Gel-NPs should not alter the binding affinity towards anti-OHG.  Only if the binding affinity is 
retained, these constructs could be used as a substrate in the sensor components.  BSA-OHG and 
Gel-BSA-OHG show serial decrease in absorption.  The absorbance values for Gel-NPs, physical 
mixture of BSA and OHG, BSA and PBS that contain no OHG are negligible.  The results 
validate that (i) OHG is bound to both BSA and gelatin nanoparticles (Gel-NPs) (ii) the binding 
affinity towards anti-OHG is retained (iii) one of these constructs can be used as substrates to 
mimic OHG for lateral flow (Figure 65).  Upon observing the absorbance changes, it is very 
clear that Gel-BSA-OHG shows incremental and proportional changes compared to BSA-OHG 
and OHG. Therefore, Gel-BSA-OHG appears to be an ideal candidate and can be utilized as 
immobilization substrate for OHG. 
 
Figure 65 Standard curve of competitive ELISA with Gel-BSA-OHG, BSA-OHG and OHG 
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3.3.5 Detection of 8-OHdG using Gel-BSA-OHG 
Competitive ELISA was performed to evaluate the efficiency of Gel-BSA-OHG to detect OHDG 
in varying concentrations. Two different ELISA experiments were performed. For the first 
experiment, anti 8-OHdG conjugated with gold nanocluster(fAuNC-Antibody) was used for 
testing while in the second experiment 1 µg/ml anti-8-OHdG antibody was used for testing. Gel-
BSA-OHG was coated on the plate with varying concentrations on a 96 well plate followed by 
incubation with fAuNC-Antibody with varying concentrations of OHDG.  Addition of 
Secondary IgG with HRP enzyme and its subsequent reaction with the TMB substrate 
established the varying color intensity of the wells depending on the concentration of the Gel-
BSA-OHG and 8-OHdG (Figure 66).  The experiment was repeated with 1 µg/ml anti-8-OHdG 
antibody (Figure 67) at different concentrations. The experiments suggested that fAuNC-
Antibody has a high affinity towards 8-OHdG in the solution and is comparable to the binding 
affinity of anti-8-OHdG antibody. The signal intensity for fAuNC-Antibody increased with 
decreasing 8-OHdG concentration   
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From the above graphs we established that Gel-BSA-OHG can be used as a substrate for the 
detection of OHdG with a detection limit of 0.001mg/ml of 8-OHdG.   
 
 
Figure 66 Competitive ELISA with Fluorescent gold nanoclusters and 8-OHdG solution in varying 
concentrations
Figure 67 Competitive ELISA graphs with anti-8-OHdG antibody with varying 8-OHdg concentrations 
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3.3.6 Monolayer vs Multilayer coating 
 The concentration and volume of Gel-BSA-OHG plays a crucial role in the efficient detection of 
8-OHdG. Two different experiments were conducted to determine the concentration and volume 
of the Gel-BSA-OHG for the maximum efficiency of 8-OHdG detection.  In one experiment a 
monolayer coating of Gel-BSA–OHDG (60l) was added for the competitive ELISA experiment 
while in the second experiment a multilayer coating (100l) of Gel-BSA-OHG was used and 8-
OHdG was detected (Figure 68).  From the ELISA plot, it is clear that monolayer coating of Gel-
BSA-OHG results in a more uniform standard curve compared to multilayer and is suitable for 8-
OHdG detection.  ELISA experiments were repeated with a 1g/ml concentration of the Gel-
BSA-OHG , and compared with a standard ELISA kit with BSA-OHG substrate which is 
commercially available. The standard curves of the Gel-BSA-OHG substrate had a more linear 
trend as compared to the commercially available JAICA kit. We concluded that GEL-BSA-OHG 
at a concentration of 1 g/ml could be used a robust substrate for the competitive ELISA.  
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3.3.7 Interference Studies 
The human urine is composed of several components like urea, sodium, potassium, creatinine 
and other dissolved ions. The Gel-BSA-OHG and Au-anti-8-OHdG conjugate should not have 
any interference with the other components of the urine and should be able to detect only the 
amount of 8-OHdG present in the sample. Competitive ELISA was performed on a 96 well plate 
with Gel-BSA-OHG as the substrate and varying concentrations of 8-OHdG was added to the 
artificial urine sample.  ELISA results demonstrated that the colorimetric intensity decreased 
with increasing 8-OHdG concentrations, validating the utility of the substrate (Figure 69 a, 69 b). 
 
Figure 68 Competitive ELISA graphs of Multilayer vs. Monolayer coating of Gel-BSA-OHG with anti-8-OHdG antibody 
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a) b)  
3.3.8 Paper strip assay (LFIA) 
The paper strip assay was assembled on a nitrocellulose membrane. The conjugate pad was 
coated with Au-antiOHdG. The test pad was coated with Gel-BSA-OHG substrate and the 
control pad was coated with Anti mouse IgG (secondary antibody). The paper strip which was 3 
mm wide and 6 cm long was used as a dip sensor. The paper strip was dipped in OHDG solution 
of varying concentrations and the colorimetric intensity of the test line was captured using a 
smartphone(X. Zhu et al., 2014). The images obtained were analyzed using ImageJ software. The 
intensity of the test line decreased with increasing concentration of the 8-OHdG concentrations. 
The intensity of the test lines was normalized with the background intensity of the nitrocellulose 
membrane for all the images. The color of the test line started to appear within 1 hour of the 
initiation of the experiment (Figure 70).  A test was conducted to confirm that the strip does not 
react with other components of the human urine. The strips were dipped in artificial urine added 
with varying concentration of 8-OHdG and the intensity of the test line was captured through a 
smartphone camera and the images were analyzed through ImageJ software. The strips did not 
seem to interfere with any of the other components of the artificial urine and exhibited a 
decreasing intensity with increasing 8-OHdG concentrations.  There was 99% correlation 
between ELISA studies with PBS and artificial urine (Figure 71).   
Figure 69 a) ELISA with 8-OHdG in PBS b) ELISA with 8-OHdG in Artificial Urine  
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3.3.9 Analysis of Clinical Urine samples 
Urine samples were collected from patients with known history of diabetes from the Mason Eye 
Institute at the University of Missouri, Columbia. Samples were collected with patients who 
were diagnosed with DR with Fundus examination and from patients who did not DR. The urine 
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Figure 71 Interference studies with Artificial Urine for LFIA based paper assay 
Figure 70 8-OHdG analysis with LFIA (Standard curve) 
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samples were collected during the day and were stored in -20oC till they were analyzed. The 8-
OHdG level in the urine samples was analyzed using 96 well competitive ELISA as well as 
lateral flow based paper strip assay. Standard curves with known 8-OHdG concentrations were 
used as control.  The values of the 8-OHdG were normalized with creatinine levels in the urine. 
The 8-OHdG (ng/ml) values and creatinine (mg/dl) values of the patients were correlated with 
the Fundus result of the patient. The distribution of the 8-OHdG values of the patients showed 
around 65% correlation with the Fundus results (Figure 72 a). However, there was negligible 
correlation (20%) with creatinine values of patients with the DR status of the patients (Figure 72 
b).The 8-OHdG/creatinine values as obtained by competitive ELISA were correlated with the 
fundus results. A student t-test was performed to compare the differences between the values of 
8-OHDG of patients with and without DR and the average p value was found to be p<0.01 
indicating good correlation.    The average values of 8-OHdG in patients with DR was higher 
than that in the patients with no DR with a correlation with the Fundus results of about 80% 
(Figure 73). The urine samples were also analyzed using LFIA paper sensor. The distribution of 
8-OHdG/creatinine values was higher in patients with DR as compared to patients with no DR 
(Figure 74).   The 8-OHdG/creatinine values were correlated with the Fundus results as well as 
with the ELISA results. There was around 85% correlation of the LFIA results with the Fundus 
results, while there was around 80% correlation of the LFIA results with the ELISA results. The 
individual Fundus images of the patients with and without DR were matched with the 8-OHdG 
values for some patients (Figure 75). Around 6 outliers were observed.  Thus, based on our 
studies, the cut off value for 8-OHdG/ creatinine values for the onset of DR is approximately 35- 
45 ng/ml which corroborates with  the clinical study performed in Asian population.(Hinokio et 
al., 2002)  This is a combined cut off value for both men and women. 
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Figure 72 Distribution of a) 8-OHdG (ng/ml) values for Patients with and without DR b) Creatinine (mg/dl) values for 
patients with and without DR
Figure 73 Distribution of 8-OHdG/creatinine values of patients with and without DR as analyzed by competitive ELISA 
assay 
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3.4 Conclusion 
Diabetic Retinopathy is a microvascular complication of DM which affects the retina and is the 
leading cause of blindness among adults worldwide. DR is an asymptomatic disease, and the 
symptoms of the disease appear only after the disease has reached advanced stages. The current 
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Figure 74 Distribution of 8-OHdG/Creatinine values in patients with and without DR as measured by LFIA 
Figure 75 Fundus Images of patients with and without DR  
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method of diagnosing DR is Fundus photography or Fluorescein angiography. However, the 
symptoms indicate that the retinal damage has been developing over several years. The incidence 
and severity of DR can be controlled if there is regular screening of the patients. It is thus crucial 
to identify a biomarker that can be correlated with the onset of DR. Hyperglycemia causes the 
activation of several metabolic pathways in the retinal cells which leads to production of 
Reactive oxygen species (ROS) that leads to oxidative stress. The ROS produced in the cells 
enters the mitochondria and causes mitochondrial dysfunction which causes the guanine base 
pair in the mitochondrial DNA to oxidize to hydroxyl groups (8-OHdG). The cells remove the 
DNA lesion which is then secreted to the blood and finally to urine. Thus, urinary 8-OHdG is 
marker of the extent of DNA damage in the body. Since, retina is the region of highest metabolic 
activity, it is considered that the amount of 8-OHdG in the urine will be indicative of the extent 
of damage in the retina in a patient with DR. We hypothesized that the amount of urinary 8-
OHdG will be higher in patients with DR than with patients with no DR. To prove our 
hypothesis we conducted a two tiered study. First we developed a Gelatin-BSA-OHG substrate 
and Au-antiOHdG against 8-OHdG substrate for competitive ELISA and LFIA. We then tested 
the specificity and detection limit of the 8-OHdG for each of the sensors. Interference and proof 
of principle studies were conducted with artificial urine and varying concentrations of 8-OHdG. 
We collected urine samples from patients with or without DR from the Mason Eye Institute at 
University of Missouri (n=80) and performed these assays. 8-OHdG levels were quantified with 
competitive ELISA and LFIA methods. The DR status of the patients was confirmed. The results 
suggest that 8-OHdG levels are higher in patients with DR than with no DR and 8-OHdG can be 
explored as screening biomarker for the onset of DR 
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APPENDIX 
 
PART 2: NANOPARTICLES FOR THERAPEUTICS AND DRUG 
DELIVERY 
 
CHAPTER 4 
TARGETED DRUG DELIVERY FOR BREAST CANCER CELLS 
 
4.1 Introduction 
4.1.1 Breast Cancer 
Breast cancer is one of the major cancers affecting women worldwide. It was reported that there 
were around 246,660 new cases of breast cancer in 2016 (Breast cancer facts and figures, ACA, 
2016). It is the primary cause of death amongst women with cancer (Eccles et al, 2013).  Breast 
cancer has currently become a global health concern.   In the past few decades, several treatment 
procedures and chemotherapy drugs have been developed to combat the malignancy of the 
disease. As a result there has been a significant improvement in the cancer survival rate among 
patients (Weigel et al, 2010). The most commonly used chemotherapy drugs are Methotrexate, 
Doxorubicin, Paclitaxel, 5-fluorouracil and Gemcitabine (Singh et al, 2017).  However, in spite 
of advances in drug therapy, 14% of the all the cancer deaths in the USA in the year 2016 were 
attributed to breast cancer (Singh et al, 2017). The main causes of death due to breast cancer are 
drug resistance, metastasis and toxic side effects of the chemotherapy drugs. The major 
limitations of the cytotoxic chemotherapy are high toxicity, rapid elimination from the 
circulatory system and accumulation in non-targeted tissues or organs. (Kumari et al, 2015)) 
Target specificity of cancer drugs is thus essential for effective cancer treatment. To this effect, 
different drug carrier and delivery systems have been studied to improve the drug delivery 
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efficiency. Nanoparticles and Nano-scaled can potentially improve delivery of drugs into the 
cells through the EPR (Enhanced permeability and retention) effect and protect the therapeutic 
agents from being degraded in the biological system (Singh et al, 2017)  
4.1.2 Drug Delivery Systems in Chemotherapy 
Conventional chemotherapy drugs have poor aqueous solubility and have large pharmacokinetic 
volume of distribution. In addition, they have lower retention rates in the system and lack 
specificity of targeting. Some of the issues of conventional chemotherapy drugs can be 
circumvented by using nanoparticles or Nano scaled drug carriers (Kumari et al, 2015).  The 
nano scale size of these carriers renders them with larger surface to volume ratios which 
increases surface functionalization efficiency and also plays a crucial role in bio distribution in 
vivo.  The most commonly used drug carriers are categorized as protein based, organometallic, 
nucleic acid and liposome based (Bahrami et al, 2017). The protein based carriers generally 
include albumin, gelatin, and other polymeric nanoparticles. The organometallic carriers 
primarily comprise gold and magnetic nanoparticles.  The nanoparticles offer several advantages 
over conventional chemotherapy systems. They enhance the therapeutic index of the 
chemotherapeutic agents and improve drug efficacy by extending the half-life of the drug and 
increasing the time of circulation in the system. They also enable controlled release of the drugs 
and can be conjugated with a molecule that can specifically bind to certain receptors, thereby 
increasing target specific drug delivery in the cells and reducing non-specific drug toxicity ( 
Kumari et al, 2015). In addition, metallic nanoparticles have certain optical, physical and 
electromagnetic properties which enable them to be imaged in vivo without the need of any 
fluorescent labels. The magnetic nanoparticles have unique magnetic nanoparticles which enable 
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them to be imaged using MRI (Magnetic resonance imaging) and gold nanoparticles can be 
imaged using PET (Position emitted tomography) scan (Choi et al,2004).  
4.1.3 Hypothesis and Proposed Drug Delivery system 
There are several chemotherapy drugs that are currently being used for breast cancer. 
Methotrexate is a common drug that was initially used to treat rheumatoid arthritis (Hall et 
al,2017). However, in the recent years Methotrexate has also been widely used to treat breast 
cancer, head and neck carcinoma and certain types of leukemia (Sanyog, 2012),  It is an anti-
metabolite i.e. it affects or blocks the de novo synthesis cycle of the cells which produces 
pyrimidine and purines essential for cell growth and proliferation. Conventionally, methotrexate 
is administered orally or intramuscularly. The uptake of methotrexate in the cells is mediated by 
a saturable transporter called RFC 1 (Reduced Folate carrier) (Ceonstein, 2007). Methotrexate 
has been reported to accumulate in the extravascular pool.  Methotrexate has a short half-life of 
around 6-8 hours and does not have any detectable traces in the serum after 24 hours. Part of the 
methotrexate absorbed by the cells is converted to 7-hydroxymethotrexate, which in turn are 
converted to Methotrexate polyglutamates (MTX Glu). MTX Glu are stored in liver tissues and 
erythrocytes. The efficacy of the drug is dependent on the concentration of MTX Glu in the 
tissues (Ceonstein, 2007). 
4.1.3.1 Mechanism of action of Methotrexate 
Methotrexate is a folic acid antagonist. It inhibits several key enzymes like dihydrofolate 
reductase (DHFR) that are responsible for the synthesis of purine and pyrimidines (8). Blocking 
of the DHFR results in decrease in tetrahydrofolate (THF) levels which leads to reduced DNA 
methylation, inhibition of Thymidylate Synthase (TS) and disrupts DNA synthesis in the cells. 
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Mtx also blocks the 5-aminoimidazole-4-carboxamideri ribonucleotide (AICAR) tranformylase 
which inhibits the de novo purine synthesis (Wilson et al, 2014). 
 
 
 
Methotrexate blocks the purine and pyrimidine synthesis of DNA in cells. It arrests the cell 
development in the S phase of the cell cycle and induces apoptosis of the cells. In addition to 
blocking the purine/pyrimidine synthesis, few reports have shown that methotrexate 
downregulates the JAK/STAT pathway in certain melanoma cells. JAK/STAT is a cell 
proliferation promoting pathway which is upregulated in a cancer cell. When methotrexate is 
uptaken by the cell, it is hypothesized that it down regulates the JAK/STAT pathway and in the 
process starts a cascade of pathways which also induce apoptosis (Thomas et al, 2015). 
Figure 1 Schematic of mechanism of purine/pyrimidine blocking pathway of Methotrexate 
125 
 
 
 
 
 
 
 
 
Figure 2 Molecular pathways in a cancerous cell line before methotrexate treatment 
Figure 3 Molecular mechanisms in cancer cells after methotrexate treatment 
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Methotrexate suffers from certain limitations which include the short half-life of the drug, rapid 
diffusion through the body and harmful side effects due to uniform tissue distribution ( Bostik, 
1988).  
It has been reported clinically that the side effects of the methotrexate can be alleviated by 
administering folic acid which competes with methotrexate for the same transporter (RFC1). 
Folic acid is also used as a targeting agent for Folate receptor α expressing cells. Folate receptor 
α is a glycophosphytidylinositol-anchored, folate binding protein which is overexpressed in some 
cancerous cells (Ceonstein, 2007) (Jain et al, 2011). It captures the folate or folic acid which 
captured the folate to enhance cell proliferation in cancerous cells. Thus, folic acid conjugated 
with methotrexate can be used as a targeting agent to specifically target cells expressing folate 
receptor α (cancerous cells) to block their proliferative cycle and induce apoptosis. However, due 
to short half-life of the methotrexate in the system, the effects would not be very significant. The 
half-life of methotrexate can be increased by conjugating with human serum albumin which has 
a half-life of about 19 days.  Studies have shown that conjugating methotrexate with HSA has 
increased efficacy and sensitivity (Ulbrich et al, 2011) (Bures, 2011). Thus, a methotrexate HSA 
conjugate with a folic acid as a targeting agent can be an effective tool for drug delivery. 
However, it will be difficult to track the path of the drug in the system and to know whether the 
drug is being delivered to the target tissue or being accumulated in the liver. An imaging 
modality attached to the drug conjugate will enable real time imaging and tracking of the drug 
conjugate.  
4.1.4 Magnetic nanoparticle based drug delivery system 
Magnetic nanoparticles have been reported to have important biomedical applications such as 
magnetic cell separation, targeted drug delivery, contrast agents for Magnetic Resonance 
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Imaging (MRI) (Choi et al, 2004).  The versatility of the magnetic nanoparticles can be enhanced 
by coating a metallic shell with different optical and surface properties, on the magnetic 
nanoparticle. Core-shell magnetic NPs consist of a magnetic core and a metallic shell that 
provides a hydrophilic layer to the NPS and provides a platform for surface functionalization ( 
Qunito et al, 2015). Gold salts can be reduced on the magnetic core to form a gold shell iron 
oxide core nanoparticle, which can further be functionalized with thiolated molecules. The core 
shell magnetic gold nanoparticles have unique physical and surface properties which make them 
attractive tools for drug delivery in vivo. Due to their large surface to volume ratio, the 
nanoparticles can be conjugated with drugs and targeting moieties simultaneously. Their optical 
and magnetic properties enable them to be used for different imaging modalities in vivo, e.g. 
Magnetic Resonance Imaging, PET scan and Surface Enhanced Raman scattering (SERS) 
imaging (Blasiak et al, 2013).  
Under, normal biological conditions magnetic nanoparticles do not exhibit magnetic properties 
towards each other. In an MRI scanner, when an external magnetic field is applied, the magnetic 
particles attain magnetic saturation, creating a dipolar field which leads to a significant reduction 
of proton relaxation (T2 relaxation) resulting in a much darker image of the target area over the 
biological background. These properties of the nanoparticle can thus be utilized to for imaging 
and following the path of the drug delivery tool (Figure 4) (Frey et al, 2009).  
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Figure 4 Setup of an MRI scanner in the University of Missouri, School of Veterinary Medicine 
 
Gold nanoparticles exhibit light induced surface plasmon resonance on their surface. As a result 
of this there are electric field hot spots created on the curves and troughs on the surface of the 
nanoparticles. Molecules which are near these electric field hot spots will experience enhanced 
excitation field and emit amplified Raman intensities (Shuming Nie, 2008).  Studies have shown 
that a 103 fold enhancement is attainable through SERS. Because of its unique advantages, SERS 
has become a promising tool in medical application especially for imaging in vivo. SERS can be 
used for real time imaging of drug delivery in vivo. To further enhance the SERS signals, the 
nanoparticles are tagged with a dye that emits enhanced signals under certain excitation 
wavelengths (Kho et al, 2005).  
We have conjugated methotrexate to human serum albumin and attached it to folic acid.  The 
methotrexate human serum albumin and folic acid conjugate is attached to gold coated iron oxide 
nanoparticles to enable monitoring the path of the drug moiety to its target with MRI. The 
amount of methotrexate released can be monitored using SERS imaging by the dye attached to 
the gold conjugated iron oxide nanoparticle. Characterization experiments were conducted on the 
nanoparticle conjugates. SERS and MRI imaging was done on the Au@Fe nanoparticles in vitro.  
Cytotoxicity and cellular uptake studies were conducted to test the efficacy of the nanoparticle 
conjugate in breast cancer cell lines.    
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4.2 Materials and Methods 
4.2.1Materials 
 FeCl3.6H2O, FeCl2.4H2O, Human Serum Albumin (HSA), Folic Acid (FA), 
Hydroxysuccinimide (NHS) were purchased from Sigma Aldrich. Tetramethylammonium 
hydroxide (TMOH) and Tri sodium citrate were purchased from Acros Organics. Hydrochloric 
acid (HCl), Nitric Acid (HNO3) and Sodium Hydroxide (NaOH) were purchased from Fisher 
Scientific. Methotrexate was purchased from ToCris. 1-Ethyl-3dimethylaminopropyl) 
carbodiimide (EDC) was purchased from Fluka Analytical. DI water was used in all 
experiments.  
4.2.2 Instrumentation  
UV Vis absorbance of Au@Fe nanoparticles was measured with Varian CaryUV  
Spectrophotomer. The UV Vis absorbance of MTX HSA FAwas measured with BioTek Epoch 
microplate reader and Cytation 3.   Zeta Potential and hydrodynamic radius was measured using 
Malvern Zeta sizer.  TEM Images were taken with Jeol 1400 Biological TEM.  XRD studies 
were conducted using FEI Tecnai F30 G2 Twin Microscope.  The images were analyzed using 
ImageJ analysis software. 1D and 2D NMR studies were conducted by Dr. Raj Bhaskaran’s 
group. 
 
4.2.3Synthesis of Fe3O4 and γFe2O3 
 The Fe3O4 nanoparticles were synthesized in nitrogen atmosphere following previously reported 
procedure(Deng et al, 2003) . Briefly, 5.2 g of FeCl3 and 2 g of FeCl2 were dissolved in 25ml of 
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DI water. 0.85ml of 12.1N HCl was added to the solution and stirred vigorously until the Fe salts 
were dissolved. 250 ml of 1.5M NaOH was added drop wise into the mixture with vigorous 
stirring, resulting in an initial pale yellow solution which changed to brown and finally to black. 
The black precipitate was washed twice with H2O and once with 0.1M TMOH 
(Tetramethylammonium hydroxide) with magnetic separation. To obtain γFe203 nanoparticles, 
Fe3O4 nanoparticles were washed with 0.01M HNO3 and then dissolved in 0.01M HNO3 at 90°C 
with magnetic stirring until complete dissolution. The Fe3O4 nanoparticles were separated 
through magnet and re-suspended in 0.1M TMOH at pH 11 after washing with water. 
4.2.4 Synthesis of Au@Fe 
Iron oxide nanoparticles were coated with reduced gold nanoparticles (Pham et al, 2008). Sodium 
citrate was used as the reducing and stabilizing agent. The gold coated iron oxide nanoparticles 
were prepared according to a previously published procedure with slight modifications. Briefly 1 
ml of TMOH stabilized γFe2O3 solution was magnetically separated and the pellet was dissolved 
in 1 ml DI water. The solution was added to 50ml 0.01M sodium citrate solution and stirred for 30 
minutes. This is referred to in the paper as the working solution. 5ml of the working solution was 
added to 40 ml 0.01M sodium citrate solution followed by sonication for 15 minutes. The solution 
was heated till boiling and 0.01M HAuCl4 was added. The solution was stirred at that temperature 
for 15 minutes. The color changed to deep red. After 15 minutes the solution was removed from 
heat and stirring was continued for another 15 minutes till the temperature of the solution reached 
room temperature. The solution was purified by magnetic separation.  HSA was conjugated to 
Au@Fe NP and the binding has been confirmed. 5 mg of Human Serum Albumin (HSA) in DI 
water was added to 2 mL of Au@Fe nanoparticle and allowed to stir overnight. Excess HSA was 
removed from the solution via magnetic separation. The excess HSA in the supernatant and the 
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pellet were separated and used for Enzyme-linked Immunosorbent Assay (ELISA) to detect the 
presence of HSA in nanoconjugate. The purified HSA-Au@Fe pellet was characterized by UV-Vis 
and Zeta potential measurements.  
4.2.5 Synthesis of MTX HSA FA Conjugates 
10 mg MTX and 10mg Folic Acid was dissolved in 1ml 0.1M NaOH (pH~12) (Stehle G, 1997).  
14mg EDC and 50mg NHS was added and the solution was activated by stirring at room 
temperature for 3 hours. Following MTX and Folic acid activation, 15mg/ml HSA was added 
and stirred for 1 hour at room temperature. The solution was purified by centrifugation with 
10kDa filter at 5000 g for 8 minutes. 10 mg MTX was dissolved in 1ml 0.1M NaOH (pH~12).  
7mg EDC and 25 mg NHS was added and the solution was activated in a shaker at 37C for 3 
hours. Following MTX and Folic acid activation, 15mg/ml HSA was added and stirred for 1 hour 
at room temperature. The solution was purified by centrifugation with 10kDa filter at 5000 g for 
8 minutes.  HSA FA was prepared according to previously published procedure. Briefly Folic 
acid was dissolved in 1ml 0.1M NaOH solution. 800 µl of the FA solution was taken and 200µl 
of 11.22mg/ml EDC solution was added. The solution was kept in a thermomixer at 20oC and 
shaken at 1000rpm for 15 minutes. 15mg/ml HSA solution was added and the mixing was 
continued for one hour.  The solution was passed through 10kDa filter and centrifuged at 5000g 
for 8 minutes. This purification step was repeated three times.  
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4.2.6 Conjugation of MTX HAS FA to Au@Fe 
 MTX-HSA-FA was conjugated to Au@Fe-PEG nanoparticles using EDC-NHS conjugation. 
1ml of Au@Fe-PEG was centrifuged at 15,000g and the pellet was dissolved in 200ul of MES 
buffer. 4mg EDC and 5 mg NHS was  
4.2.7 Tryptic digestion of MT HSA FA and peptide mapping 
 An aliquot (60ug – 4ul) was removed from the original submission and diluted with 16uL 6M 
urea, 100mM HEPES, pH 8.0 and then digested with trypsin according to our standard protocol.  
Following digest, the samples were acidified to 1% using formic acid, and 25uL transferred to 
autosampler vials.  The vials were placed in a thermostatted (7C) autosampler.  An aliquot (full 
loop, 18uL) of the sample was loaded onto a C8 trap column (Pepmap100 C8 trap column 
Dionex/Thermo Scientific).  Bound peptides were eluted from this trap column onto a 25cm x 
150µm inner-diameter pulled-needle analytical column packed with HxSIL C18 reversed phase 
resin (Hamilton Co).  Peptides were separated and eluted from the analytical column with a 
continuous gradient of acetonitrile at 400nL/min.  The Proxeon Easy nLC system is attached to 
an LTQ Orbitrap XL mass spectrometer.  Initial conditions during trap loading were 5%B (A: 
0.1% formic acid in water, B: 99.9% acetonitrile, 0.1% formic acid), followed by 2min at 5%B 
during trap loading, gradient of 5-20%B over 20min, gradient of 20-30%B over 35min, gradient 
30-90%B over 5 min, hold at 90%B for 22min, ramp back to (1min) and hold at initial 
conditions for 5min.  Total run time was 90min. FTMS data were collected (30,000 resolution, 1 
microscan, 300-1800m/z, profile) and then each cycle (approximately 3 seconds) the 9-most-
abundant peptides (ignore +1 ions, >1000 counts) were selected for MSMS (2m/z mass window, 
35% normalized collision energy, centroid).  Raw data were copied to the Sorcerer2 IDA (SageN 
Research) and peak lists prepared using ReAdW.  The NCBInr database limited to Human (last 
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update 2/6/2013, 693,522 entries) was searched with trypsin as enzyme, 2 missed cleavages 
allowed; carbamidomethyl cysteine as a fixed modification; oxidized methionine, methotrexate, 
and folic acid as variable modifications; 50ppm mass tolerance. 
All search data were examined using Scaffold V3.4.8.  All data were filtered based on the 
following criteria: 5 peptide minimum, 95% confidence on peptide ID, mass error limit of <10ppm, 
99.0% confidence on protein ID. Manual analysis of putative modified peptides was conducted to 
validate modification  
4.2.8 MRI Phantom images and solution Images 
Transverse relaxation (T2 decay) of Au@Fe-MTX HAS FA, Au@Fe-HSA and Au@Fe was 
utilized to generate a dark MR image in this study. Upon accumulation in agar matrix Au@Fe 
typically acts as T2 contrast agent to provide a dark image and the contrast enhancement is 
proportional to the concentration of Fe in the construct.  The samples are inducted in agar balls 
and placed in decreasing order of concentration clockwise.  It is a spin echo sequence that has an 
180o inverse pulse applied prior to the SE. 
4.2.9 Cell Studies    
MDA MB 231 which is a folate receptor α positive cell line and also a TNBC was used as a positive 
control. MCF7 which has been reported to have low folate receptor α expression was used as 
negative control. NIH 3T3 was used as a non-cancerous cell line. Cells were grown in RPMI media 
(ATCC) with Fetal Bovine Serum (Sigma Aldrich) and Gentamycine. The cells were grown in 
CO2 incubator with 5% CO2 and 37oC 
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4.2.10 Cytotoxicity Studies (MTT assay) 
MDA MB 231, MCF7 cells were sub cultured till they reached 70% confluence. 100µl of the 
cultured cells was added to each 96 well plates and seeded for 24 hours. After 24 hours, varying 
concentrations (5µg/ml, 10µg/ml, 25µg/ml and 50µg/ml) of Au@Fe MTX HSA FA, Au@Fe MTX 
HSA and Au@Fe HSA FA were added to the cell culture and incubated for 24 hours following 
which 10µl of MTT dye was added. The dye was allowed to incubate for 4 hours or till needle like 
crystal structures were visible under the microscope. The medium was removed and the crystals 
were dissolved in DMSO and the absorbance was recorded in a BioTek Epoch Microplate reader 
and Cytation3 at 570 nm. The absorbance data was collected by Gen5 software and analyzed with 
MS excel. Experiments were conducted in triplicate for statistically significant results. Similar 
study was repeated with NIH 3T3 cell lines in custom RPMI media.  
4.2.11 Cellular uptake studies 
Glass cover slips were added to 6 well plates.  1ml Poly L lysine solution was added directly to 
the cover slip and was kept at RT for 2 hours. After 2 hours Poly L lysine was removed and the 
coverslips were dried at RT. MDA MB 231 and MCF7 cells were subcultured and 500µl of the 
cells were seeded in the wells.  The cells were seeded for 24 hours. Au@Fe HSA, Au@Fe MTX 
HSA FA nanoparticles were incubated for 2 hours and 5 hours in separate experiments. Following 
nanoparticle incubation, the cover slips were washed with PBS several times. Tween 20 was added 
to the cover slips for 5 minutes to remove nonspecific binding. Following tween washing the cells 
were washed with PBS again and fixed with PFA before transferring the cover slips to glass slides 
for imaging. The slides were stained DAPI nucleus staining dye.  To study the receptor specificity 
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of the nanoparticles, the cells were fixed with PFA and then nanoparticles were incubated for 2 
hours and 5 hours. The washing and slide mounting procedure was same as that for live cells. 
Cellular uptake studies by blocking folate mediated endocytosis pathway:The cell lines were 
preincubated with Folic acid and then same process as the cellular uptake studies for live and fixed 
cells was followed to study the uptake pathway of the nanoparticles.  
4.2.12Western Blot 
MDA MB 231 cells were seeded in a 6 well plate and treated with Au@Fe-MFH, Au@Fe and 
Methotrexate for 24 hours. Whole cell lysates were prepared using Triton X 100 lysis buffer with 
MS-Safe protease and phosphatase cocktail inhibitor (Sigma Aldrich) and protein concentration 
was equalized with Bicinchoninic acid assay (Sigma Aldrich). Proteins were separated by 4-15% 
native PAGE (Bio-Rad) and were transferred onto nitrocellulose membranes (Gen Script). The 
membranes were incubated with Primary antibody overnight at 4oC. The primary antibodies used 
for this experiment are Jak2, Stat5, Akt, ERK, BCl2, Bax, PARP and nFkB . The antibodies were 
washed and then incubated with secondary anti Mouse IgG HRP or anti rabbit IgG-HRP and 
incubated for 2 hours at 37oC. The membranes were washed and imaged on Chemidoc Biorad 
imaging system. Actin protein levels were used as a control for adequacy of equal protein loading. 
Protein expression levels were analyzed by densitometry analysis. 
4.3 Results and Discussion 
4.3.1 Characterization of MTX HSA FA Conjugates 
Human Serum Albumin was conjugated to Folic Acid.  Methotrexate was also conjugated to 
Human Serum Albumin by NHS activation separately.  Finally Human Serum Albumin was 
conjugated to Methotrexate and Folic acid through the carboxyl group by EDC and NHS 
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activation. The MTX HSA FA, MTX HSA and FA HAS conjugates were characterized by 
measuring the absorbance in UV Vis range, zeta potential and hydrodynamic radius 
measurements, NMR spectroscopy, Mass spectrometry and Trypsin digestion of the proteins 
followed by peptide mapping.HSA, Methotrexate (in sodium bicarbonate buffer) and Folic acid 
(in NaOH solution) show absorbance at 270 nm, 370nm and at around 360nm respectively.  The 
UV Vis graph of HSA FA, MTX HSA and MTX HSA FA showed an absorbance at 270 nm and 
at 370nm(Figure 5).  From the UV Vis graph we could confirm the presence of HSA and FA in 
HSA FA conjugates.  Similarly, we could confirm the presence of Methotrexate and HSA in 
MTX HSA conjugate. However, since the UV Vis graph of MTX HSA FA also showed a peak at 
270nm and 370 nm, we were not able to confirm the presence of both FA and MTX in the MTX 
HSA FA conjugate.  
 
  
 
 
 
Figure 5 UV-Vis absorbance graph of MTX-HSA-FA conjugates 
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4.3.2 Trypsin Digestion and Peptide Mapping 
To further corroborate the conjugation of MTX and FA to the HSA, Trypsin digestion and 
peptide mapping experiments were conducted by the DNA core in University of Missouri. The 
sequence mapping data demonstrated one published MTX site and two unpublished MTX sites. 
Seven published HSA sites in HSA-FA were found to be modified by FA. In MTX-HSA-FA, 
two published sites were modified by FA and one was modified by MTX. There were other sites 
of MTX and both MTX and FA were observed. Hence, from the peptide sequence mapping data, 
we concluded that both MTX and FA were conjugated to HAS (Figure 6).  
 
 
Figure 6 Trypsin digestion and peptide mapping data for published and observed sites of MTX and FA in MTX-HSA, FA-
HSA and MTX-HSA-FA conjugates
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4.3.3 Characterization of Au@Fe and Au@Fe-MTX-HSA-FA conjugates                           
 Gold conjugated Iron oxide nanoparticles were synthesized using previously published method 
using sodium citrate as a reducing and stabilizing agent with some modifications.   The gold 
conjugated iron oxide nanoparticles showed a broad peak at 540nm. This result was in agreement 
with previously published values.  The citrate stabilized gold nanoparticles show an absorbance 
peak at 520 nm. The red shift is because of the increased hydrodynamic radius of the Au@Fe 
conjugate.  The UV Vis graph for Au@Fe MTX HSA FA conjugates showed a broad peak at 
540nm along with peaks at 370nm and 270 nm (Figure 7).   
 
To determine the stability of the nanoparticles, zeta potential was measured with DTS Nano 
Zetasizer. Dynamic Light scattering was used to measure the Hydrodynamic radius of the gold 
conjugated iron oxide nanoparticle. Size and shape of the nanoparticles were confirmed by the 
images taken by Transmission Electron Microscopy.  From the TEM images, we observed the 
gold particles were layered on the iron oxide nanoparticles forming a sheet like structure. The 
average diameter of the nanoparticles was 30±5nm (Figure 8) .  
Figure 7 UV absorbance graph of Au@Fe and Au@Fe-MTX-HSA-FA 
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  Atomic absorption spectrometer was used to measure the concentration of gold in the Au@Fe 
nanoparticle solution. 200 µl of the Au@Fe solution was digested in HCL and HNO3 solution 
and the volume was made up to 10ml with DI water. The diluted Au@Fe solution was analyzed 
under Atomic Absorption Spectroscopy.  We estimated the gold concentration to be 20µg/ml of 
Au@Fe solution. 
SERS Imaging:The Au@Fe nanoparticles were functionalized with Thiol -PEG-750 and then 
coated with Rhodamine B isothiocyanate (SERS reporter dye). The Au@Fe-Peg-Rhodamine B 
isothiocyanate conjugate was diluted in DIW. The samples were coated on a 76 GA grating. The 
gratings were analyzed by Reninshaw InVia Raman Microscope. The Au@Fe-Rhodamine 
conjugate displayed a higher Raman Signal as compared to Au@Fe-Peg nanoparticle. 
Figure 8 TEM Image of Au@Fe-MTX-HSA-FA conjugate 
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4.3.4 MRI Imaging 
T2 relaxation Images were recorded on MRI scanner. Solutions of Au@Fe at varying 
concentrations were used for the experiment. The intensity of the images was directly 
proportional to the concentration of the solution (Figure 10). Phantom Images of the Au@Fe at 
different concentrations also demonstrate increasing intensity with increasing concentrations. 
Thus, the Au@Fe nanoparticles can be used as MRI contrast agents even when they are 
functionalized with surface modification agents. 
Figure 9 Raman signal for Au@Fe and Au@Fe-Rhodamine B isothiocyanate coated on a glass, silver and 76 GA grating 
141 
 
 
 
 
Figure 10 MRI Images of Au@Fe solutions at different concentrations 
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4.3.5 Cytotoxicity Assay (MTT Assay) 
Cell viability studies were conducted using 4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide (MTT) dye.  We tested the cytotoxic effects of MTX, Au@Fe MTX-HSA FA, Au@Fe 
MTX-HSA and Au@Fe on two different cell lines.  The IC 50 values for MTX in MCF7 cell line 
was around 6.25ug/ml while for the AF-MFH conjugate it was 3.125ug/ml. The cell viability 
decreased consistently with increasing concentration of the drug conjugate. For the MDA MB 
231 cell lines, the IC 50 of the cell lines decreased from 6.25ug/ml with the drug to 3.125ug/ml 
with the Au@Fe-MTX-HSA-FA conjugates. 
Figure 11 MRI Images of Au@Fe Phantom Gels at different concentrations 
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 4.3.6 Cellular uptake studies (Cytoviva Imaging) 
To study the uptake of the nanoparticles in cells, we seeded the cells on a cover slip and 
incubated the cells with nanoparticles for about 5 hours. The cover slips were stained with DAPI 
Dye and the slides were observed under a Cytoviva microscope. We noticed increased uptake of 
Figure 12 Cytotoxicity assay result of AF-MFH, AF-MH, AF, MTX in MCF7 cell line 
Figure 13 Cytotoxicity assay result of AF-MFH, AF-MH, AF, MTX in MDA MB 231 cell line 
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Au@Fe MTX HSA FA and Au@Fe MTX HSA in MCF7 cell line. Not much significant uptake 
was noticed for Au@Fe HSA nanoparticles.  
Au@Fe-MFH 
 
 
 
 
 
 
 
Figure 14 Cellular uptake of AF-MFH in MCF7 and MDA MB 231 cell lines 
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Au@Fe‐MH 
 
Au@Fe 
 
 
Figure 15 Cellular uptake of AF-MH in MCF7 and MDA MB 231 cell lines 
Figure 16 Cellular uptake of AF in MCF7 and MDA MB 231 cell lines 
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4.3.7 Western Blot 
The expression of Jak2 ans Stat5 proteins were analyzed using Western blot. We observed that 
Jak2 and Stat5 were down regulated in Au@Fe-MFH conjugate. The apoptotic marker proteins 
Caspase3, Cleaved PARP and Bcl2 were upregulated in the drug treated cells. The results 
corroborated with the published literature.  
 
 
4.4 Conclusion  
We conjugated Methotrexate to HSA and then conjugated it to FA as a targeting moiety. 
Characterization studies with MTX-HSA-FA (MHF) demonstrated that both FA and MTX were 
competitively binding to HSA. The MHF conjugated was conjugated to Au@Fe to enable drug 
delivery into the cells and for imaging. Cell cytotoxicity assays were conducted on MCF7 and 
Figure 17 Western Blot images and analysis of protein expression in MDA MB 231 cell lines after MTX, AF-MHF and AF 
treatment
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MDA MB 231 cell lines to assess the efficacy of the drug conjugate in comparison with 
methotrexate. The drug conjugate lowered the IC 50 of the cell lines and cellular uptake studies 
demonstrated that the target receptor mediated endocytosis took place. Blocking of the FA 
demonstrated that there was limited uptake with folic acid drug conjugate. Western blot studies 
were conducted to establish the molecular pathways that are triggered in the cell lines. We 
observed that the Jak/Stat pathway is downregulated when the cells are treated with drug 
conjugate. The apoptosis initiation proteins like caspase3, Bcl2 and cleaved PARP were 
upregulated in the cells. Thus, we demonstrated that MTX-HSA-FA conjugated to Au@Fe is an 
efficient drug delivery tool for targeting folate receptor expressing breast cancer cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
148 
 
Addendum to Chapter 1  
Design of Microfluidic chip with small pits 
 
 
Figure 18 Microfluidic chip design for filtering and capturing small cells based on size 
 
 
Figure 19 Conceptual microfluidic pit design for capturing small cells and filtering larger 
particles under aunidirectional flow and reverse flow lift-off 
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Figure 20 Comsol Simulation of fluid flow along the small pits 
 
 
 
Figure 21 Microfluidic chip design for filtering and capturing larger cells based on size 
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Figure 22 Conceptual microfluidic pit design for capturing large cells and filtering smaller 
particles under aunidirectional flow and reverse flow lift-off 
 
 
 
Figure 23 Comsol simulation of fluid flow across a large pit 
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